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ABSTRACT 
 
Bioequivalence determines if two drugs are alike.  The three kinds of bioequivalence are 
Average, Population, and Individual Bioequivalence.  These Bioequivalence criteria can 
be evaluated using aggregate and disaggregate methods.  Considerable work assessing 
bioequivalence in a frequentist method exists, but the advantages of Bayesian methods 
for Bioequivalence have been recently explored.  Variance parameters are essential to 
any of theses existing Bayesian Bioequivalence metrics.  Usually, the prior distributions 
for model parameters use either informative priors or vague priors.  The Bioequivalence 
inference may be sensitive to the prior distribution on the variances.  Recently, there have 
been questions about the routine use of inverse gamma priors for variance parameters.  In 
this paper we examine the effect that changing the prior distribution of the variance 
parameters has on Bayesian models for assessing Bioequivalence and the carry-over 
effect.  We explore our method with some real data sets from the FDA. 
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1.  INTRODUCTION 
Bioavailability is defined as the amount or the rate at which a drug is absorbed 
into the circulatory system or becomes available at the site of physiological activity after 
administration (Merriam-Webster’s Medical Dictionary, 2002).  Two drug formulations 
are considered bioequivalent if the bioavailability for each drug formulation is similar in 
terms of effectiveness and safety.  Bioequivalence can be assessed using the methods of 
Average Bioequivalence (ABE), Population Bioequivalence (PBE), and/or Individual 
Bioequivalence (IBE).  Establishing Average Bioequivalence statistically involves 
comparing the average bioavailability of each population that receives the two drug 
formulations.  Establishing Population Bioequivalence statistically involves ascertaining 
the population averages of the two drug formulations and also comparing the variability 
of the bioavailability of each population that receives the two drug formulations.  Having 
statistical knowledge of the Population Bioequivalence of two drug formulations assists 
physicians in deciding which drug formulation to prescribe pharmaceutically (Chow and 
Liu, 1995).   Not only can bioavailability vary between populations, but it can also vary 
from person to person and within each person of the population.  The variability of the 
bioavailability from person to person is called “Between-subject “or “Inter-subject” 
variability.  The variability of the bioavailability within an individual person is called 
“Within-subject” or “Intra-subject” variability.  Assuming that each subject of each 
population receives both drug formulations, then bioavailability can also vary due to the 
subject-by-formulation interaction.  Establishing Individual Bioequivalence statistically 
involves ascertaining the population averages of the two drug formulations and also 
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comparing the intra-subject variability and/or the subject-by-formulation interaction of 
the two drug formulations.  Having statistical knowledge of the Individual 
Bioequivalence of two drug formulations assists physicians in making the pharmaceutical 
decision of whether or not a patient can switch from one drug formulation to another and 
still maintain the same efficacy (Chow and Liu, 1995).  Population and Individual 
Bioequivalence can be evaluated by aggregate and disaggregate methods.   Aggregate 
methods combine the main characteristics into one null hypothesis with a single criterion, 
while disaggregate methods have separate hypotheses for the main characteristics 
(Erickson, Seaman, Stamey, 2005). 
The United States Food and Drug Administration’s (FDA) 2001 Guidance 
recommends using an aggregate statistical test procedure for assessing IBE.  The FDA 
uses a method proposed by Hyslop, Hsuan, & Holder (2000) under a replicated crossover 
design when examining population bioequivalence and individual bioequivalence.  The 
FDA draft guidance (1999) suggests using a standard two-period crossover design when 
assessing population bioequivalence and using a replicated two-period crossover designs 
for assessing individual bioequivalence (Ghosh and Ntzoufras, 2005).   Crossover (or 
Latin Squares) designs are the best experimental designs for bioequivalence studies 
because they enable estimation of the subject, formulation, period, and random effects; 
allow the separation of the inter- and intra-subject variations; and, if replicated, facilitate 
a way to estimate the subject-by-formulation interaction (Ghosh and Khattree 2005). 
Since the use of crossover designs in bioequivalence studies enable accountability for a 
number of the sources of variance, and since population bioequivalence and individual 
bioequivalence are both functions of variance, then it is apparent why the FDA 
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recommends the use of crossover designs for assessing population and individual 
bioequivalence. 
  Advantages of Bayesian methods for assessing bioequivalence assume that the 
unknown formulation effect is a random variable and follows a prior distribution (Ghosh 
and Khattree, 2005).  A major advantage of the Bayesian approach is that it accounts for 
a variety of sources of parameter uncertainty for variance components as well as the other 
parameter estimates (Gill 2002; Gelman et al., 2004).  Inferring whether two drug 
formulations are bioequivalent in the Bayesian approach is based upon the entire 
posterior distribution of the model parameters.  The posterior distribution of the model 
parameters can be accurately assessed by generating samples using Markov chain Monte 
Carlo (MCMC) methods (Bernardo and Smith, 1994, p. 353).  With the computation 
capabilities of computers increasing over the past several decades, and the development 
of Markov chain Monte Carlo methods and Gibbs sampling, powerful software 
applications such as WinBUGS have been created which enable sophisticated models to 
be produced based upon the Bayesian approach.   
Erickson, Seaman, and Stamey (2005) developed a Bayesian model to be 
implemented in the WinBUGS application using disaggregate methods for assessing 
ABE and PBE.  Ghosh and Ntzoufras (2005) developed a Bayesian model to be 
implemented in the WinBUGS application using aggregate methods for assessing PBE 
and IBE.  The freely available WinBUGS software is used for fitting both models, so 
vague prior distributions are used for the scale parameters of the random effects.  A paper 
by Lambert et al (2005) shows that the use of vague prior distributions in MCMC using 
WinBUGS may have an influence on any inference made.  The paper also states “in a 
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random effects model, there is especially concern about the influence of the prior 
distributions on scale parameters.”  In addition to the influence that the prior distribution 
may have on scale parameters one must decide on “the distributional form of the prior 
distribution, and whether to put the prior on the variance, standard deviation or 
precision.”  Gelman et al (2004) have also recently questioned the routine use of the 
inverse gamma prior distribution for variance parameters.  In this paper we assess the 
performance of the various prior distributions on the scale parameters for assessing 
Bioequivalence.  We also address the issue of carryover effect on IBE.  To our 
knowledge, this is the first attempt to incorporate carryover in Bioequivalence. 
 In chapter 2 we specify the model and the disaggregate criteria for assessing ABE 
and PBE.  In chapter 3 we specify the model with and without carry-over effect and the 
aggregate criteria for assessing IBE.  In chapter 4 we present the various prior 
distributions to be used for the variance parameters.  In chapter 5 we present the results, 
and a final discussion about the results is presented in chapter 6.  All of the WinBUGS 




2.  AVERAGE AND POPULATION BIOEQUIVALENCE 
The FDA recommends the use of a 2×2 or higher-order crossover design for 
assessing bioequivalence.  The higher-order crossover designs occur when the 
experiment is replicated.    Replicated crossover designs are recommended for assessing 
Individual Bioequivalence; however, the simple crossover design can be used to assess 
average bioequivalence and population bioequivalence.  In crossover designs for 
bioequivalence, there are generally two “treatments.”  One treatment is the reference drug 
formulation denoted by “R,” and one treatment is the test drug formulation denoted by 
“T.”  A replicated crossover design occurs when each subject receives more than one 
treatment of each drug formulation.  Let t = 2 denote the total number of treatments.  Let 
r denote the total number of replications.  For a standard 2×2 crossover design, r = 1.  
Each time a subject receives a drug treatment, it is called a “period.”  Let p = tr = 2r 
denote the total number of periods.  The order in which the subjects receive the drug 
formulation treatments are termed “sequences,” and the total number of sequences is 
denoted by s, where s ≥ 2. 
 
2.1.  Model Specification 
Let yijk denote the logarithm of the bioavailability for subject j in formulation k of 
sequence i.  The normal model for the data is given by  
ijkikkijiijk ey +++++= piτγαµ     (1) 
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where µ is the overall mean, αi is the fixed effect of sequence i, τk is the fixed effect of 
formulation k, piik is the fixed effect of period at which the kth formulation in the ith 
sequence is administered, γij is the random effect of subject j in sequence i, and eijk is the 
random effect of subject j in formulation k of sequence i (Vuorinen and Turunen, 1996).  
This model can be written as eγzβxy ++= , where y is the observed data vector, β is a 
vector of unknown fixed effects (sequence, formulation, and period), x is a known design 
matrix that links β to y, γ is a vector of unknown random effects of subjects, z is a known 
design matrix linking γ to y, and e is an unknown random error vector.  This model 
assumes i) homogeneity of covariance structures in the two sequences; ii) linearity of the 
statistical model; iii) γij are independent and identically distributed normal random 
variables with mean 0 and inter-subject variance 2γσ ; iv) eijk are independent and 
identically distributed normal random variables with mean 0 and intra-subject variances 
2
eRσ  and 
2
eTσ  for the two formulations respectively. 
The Bayesian model that uses disaggregate methodology for assessing Average 
and Population bioequivalence presented by Erickson, Seaman, and Stamey (2005) is 
based on the model presented above, and assumes the following: 
ijky  ~ ( )2
 
, ijkijkN εσµ , is the logarithm of the bioavailability of subject j, in 
sequence i, taking drug formulation k, where 
ijkµ  = ijmim x γβα ++ ,  
 = ikpxipspspssissii xxxxx γβββββα ++++++++ ++−+−+− ,11,1,1-s1,1 ......  
m = 1,…, s+p, where, 
 
● For m = 1,…,(s-1), βm is the fixed sequence effect, and xi,m is the sequence 
indicator 
 




● For m = s+p, βm is the fixed treatment effect, and xi,m is the treatment 
indicator 
α ~ ( )20 , ασαN , where α0 = 0, and 42 10=ασ  
βm ~ ( )2, βσηPN , is a fixed effect, where ηP = 0, and 42 10=βσ  
γij ~ ( )2, γσαN , is the subject random effect for subject j within sequence i 
eijk ~ ( )2
 
,0 keN σ , denotes the random error for subject j within sequence i taking 
treatment k 
2
γσ  : is the between-subject (inter-subject) variance 
2
 keσ  : is the within-subject (intra-subject) variance for drug formulation k
 
We use weakly informative conditionally conjugate priors on the parameters to let 
the inference be dominated by the data.  The prior distributions for 2γσ and
2
 keσ are 
discussed in Chapter 4.  The prior distributions for the scale parameters of the random 
effects in this Bayesian model may or may not influence the inferences drawn from the 
model.  The prior distributions for the scale parameters of the random effects can be put 
on the inter-subject variances ( 2eRσ  and 2eTσ ) and intra-subject variance ( 2γσ ); or on the 
inter-subject precisions (τeR and τeT) and intra-subject precision (τγ); or on the inter-subject 
standard deviations ( eRσ  and eTσ ) and intra-subject standard deviation ( γσ ).  Thirteen 
different prior distributions were used for the scale parameters of the random effects for 
this mixed-effects Bayesian model to assess the influence that the priors have on the 
inferences drawn from the model. 
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2.2.  Disaggregate Criteria for Assessing ABE and PBE 
To describe the criterion used in the disaggregate methodology for assessing 
Average and Population Bioequivalence, the following notation is used: 
µT = µ + τT, mean for test drug formulation, where µ is the overall mean and τT is 
the fixed effect of test drug formulation 
µR = µ + τR, mean for reference drug formulation, where µ is the overall mean and 
τR is the fixed effect of reference drug formulation 
2
Tσ  = 
22
eTσσ γ + , total variance (population variance) for the test drug formulation, 




Rσ  = 
22
eRσσ γ + , total variance (population variance) for the reference drug, where 
2
γσ  and 2eRσ  are as previously defined 
Average bioequivalence (ABE) can be determined by testing the following two 
one-sided hypotheses proposed by Schuirmann (1987):   
H01:  µT - µR ≥ θU versus H11:  µT - µR < θU 
and 
H02:  µT - µR ≤ θL versus H12:  µT - µR > θL 
where θL  = ln(0.8) and θU  = ln(1.25) is the range of acceptable relative bioavailability 
for the formulation means as recommended by the FDA.  Average bioequivalence is 
declared if and only if H01 and H02 are rejected simultaneously at significance level α for 
a t-distribution with n1+n2-2 degrees of freedom.  In the Bayesian model, if we let Y 
denote the data, then computing the following posterior probability tests this hypothesis: 
)|( YURTLPPAB θµµθ <−<≡  
If PAB ≥ 0.90, then average bioequivalence is declared. 
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According to Liu and Chow (1995), equivalence in variability of bioavailability 
can be determined by testing the following two one-sided hypotheses:     
H01:  LRT λσσ ≤22 /  versus H11:  LRT λσσ >22 /  
and 
H02:  URT λσσ ≥22 /  versus H12:  URT λσσ <22 /  
where λL = 0.70 and λU = 1.43 is the range of acceptable relative bioavailability for the 
test drug formulation and reference drug formulation variance components as suggested 
by Chow and Liu (1995).  Equivalence in the variability of bioavailability is declared if 
and only if H01 and H02 are rejected simultaneously at significance level α for a t-
distribution with n1+n2-3 degrees of freedom.  This is a disaggregate method for 
assessing population bioequivalence.  In the Bayesian model, computing the following 
posterior probability tests this hypothesis: 
)|/( 22 YURTLPPRV λσσλ <<≡  
After average bioequivalence is declared, if PRV ≥ 0.90, then population bioequivalence 
is declared. 
Average Bioequivalence and Population Bioequivalence can be tested 
simultaneously.  If we let { }Y|URTLA θµµθ <−<=  and { }Y|/ 22 URTLB λσσλ <<= , 
then computing the following joint posterior probability of A and B will allow for 
simultaneous testing of Average and Population Bioequivalence: 
PRVPABBAPPJT ×=∩≡ )|( Y  






3.  INDIVIDUAL BIOEQUIVALENCE 
The United States Food and Drug Administration’s draft guidance (1999) 
recommends using two-period replicated crossover designs for assessing Individual 
Bioequivalence because replicated crossover designs enable a way to estimate the 
subject-by-formulation interaction.  A two-period replicated crossover design for two 
treatments will yield a four-period design with two replications for each treatment.  In 
addition to sequence, period, treatment, and subject effects, another nuisance parameter 
to be considered in crossover designs for bioequivalence is the carry-over effect.  We 
consider two models for assessing individual bioequivalence with and without the 
assumption of carry-over effects. 
 
3.1.  Model Specification without Carry-Over Effect 
Let yijkl denote the logarithm of the bioavailability response for replicate l on 
treatment k for subject j in sequence i.  The linear mixed-effects model for the data is 
given by 
ijklijkiklkijkl ey +++= δγµ       (2) 
where i = 1, …, s indicates the sequence, j = 1, …, ni indicates the subject within 
sequence i, k = R, T indicates the drug treatment, l = 1, …, pik indicates the replicate 
number, pik indicates the number of replicates for the kth treatment in the ith sequence, µk 
is the population average response for the kth formulation, γikl is the fixed effect (period 
and sequence effects) for replicate l on treatment k in sequence i, δijk is the random 
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subject effect for subject j in sequence i on treatment k, and eijkl is the random error for 
subject j within sequence i on replicate l of formulation k  (Chinchilli and Esinhart, 1996; 
Hyslop et al., 2000).  We assume for our model piT = piR = 2. 
The assumptions for this model are:  i) the 2×1 vectors of random subject effects 
T













Ω , where 2BTσ  and 
2
BRσ  are the 
inter-subject variance components for the test and reference drug formulations 
respectively, and ρ is the correlation between the responses on the same subject 
corresponding to the two drug formulations; ii) errors eijkl are mutually independent and 
normally distributed with mean 0 and intra-subject variances 2WRσ  and 2WTσ  for the two 
formulations respectively; iii) δijk and eijkl are assumed to be mutually independent; iv) 









0γ  is applied to the nuisance 
parameters to avoid overparametrization of the model. 
The Bayesian model that uses the FDA’s aggregate methodology for assessing 
Individual bioequivalence presented by Ghosh and Ntzoufras (2005) is based on the 
model presented above, and assumes the following:
 
ijkly  ~ ( )2
 
, keijklN σµ , where, 
ijklµ  = ijkiklk δγµ ++  
µk ~ ( )200 , kkN σµ , is the population average response for the kth formulation 
µ0k ~ ( )20000 ,σµN , is a second stage hyper parameter of µk, where µ00 = 0.0 and 
42
00 10=σ  
2
0kσ  ~ Gamma (a, b), is a second stage hyper parameter of µk, where a = 10




= 104  
γikl ~ ( )2, kN γγ σµ , denotes the fixed period and sequence effects for replicate l on 
treatment k in sequence i, where  µγ = 0 and 42 10=kγσ  
δij ~ ( )Ω0,2N , denotes the random subject effect for subject j in sequence i on 













eijk ~ ( )2,0 WkN σ , denotes the random error for subject j within sequence i on 
replicate l of treatment k 
ρ ~ Uniform (-1, 1), is the correlation between the response of the same subject 
corresponding to the two drug formulations 
2
BRσ  : denotes the between-subject (inter-subject) variance for the reference drug 
formulation 
2
BTσ  : denotes the between-subject (inter-subject) variance for the test drug 
formulation 
2
Wkσ  : denotes the within-subject (intra-subject) variance for formulation k 
The prior distributions for the scale parameters of the random effects in this 
Bayesian model may or may not influence the inferences drawn from the model.  The 
prior distributions for the scale parameters of the random effects can be put on the inter-
subject variances ( 2BRσ  and 2BTσ ) and intra-subject variances ( 2WRσ  and 2WTσ ); or on the 
inter-subject precisions (τBR and τBT) and intra-subject precisions (τWR and τWT); or on the 
inter-subject standard deviations ( BRσ  and BTσ ) and intra-subject standard deviations 




BTσ  and 
2
Wkσ  to assess the influence that the priors have on the inferences drawn 
from the model. 
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3.2.  Model Specification with Carry-Over Effect 
A first-order carry-over effect is defined as the lingering effect of the treatment 
administered from the immediately preceding period on the measurement of the response 
in the current period (Chinchilli and Esinhart, 1996).  A crossover design is balanced with 
respect to first-order carry-over effects if each treatment immediately precedes every 
other treatment the same number of times (Chinchilli and Esinhart, 1996).  In a balanced 
crossover design, one nuisance parameter can be modeled as a common carry-over effect.  
The model for a balanced crossover design, which is a modification of the model in (2), 
allowing for a common carry-over effect denoted as λ is given by 







1 periodafter  occurs  sequencein    treatmentof  replicate if,1 ikl
rikl  




iklγ , where J = {(i, k, l): rikl = 1, 
for each i = 1, …, s, k = 1, …, t, and l = 1, …, pik}.  The Bayesian model for (3) assumes 
that the common carry-over effect λ follows a normal distribution with a zero mean and 
variance parameter of 104 (λ ~ Normal (0, 104)). 
 
3.3.  Aggregate Criteria for assessing IBE 
The following notation is used to describe the criterion used in the aggregate 
methodology for assessing Individual Bioequivalence as recommended by the United 
States Food and Drug Administration (FDA): 
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µT = mean for test drug formulation 
µR = mean for reference drug formulation 
2
TTσ  = 
22
BTWT σσ + , total variance (population variance) for the test drug 




TRσ  = 
22
BRWR σσ + , total variance (population variance) for the reference drug 
formulation, where 2WRσ  and 2BRσ  are as previously defined 
ρ
 





= ( ) ( ) BRBTBRBT σσρσσ −+− 122 , variance due to subject-by-formulation 
interaction
 
The FDA 2001 Guidance recommends using the following parameter to test for 
Individual Bioequivalence: 
 
criterion) scaled(Constant     when )(



































Here 2 0Wσ  is a constant with an FDA recommended value of 0.04.  Testing the following 
hypothesis identifies individual Bioequivalence: 
H0:  ΘIBE ≥ θI versus H1 ΘIBE < θI 
The FDA recommends a value of 2.4948 for θI, and Individual Bioequivalence is 
declared if H0 is rejected at significance level α.  In the Bayesian model, computing the 
following posterior probability tests this hypothesis: 
)|( YIIBEPIBEH0 θ<Θ≡  





4.  PRIOR DISTRIBUTIONS FOR SCALE PARAMETERS 
The paper by Lambert et al (2005) presents several prior distributions that can be 
used for the scale parameters of random effects in Bayesian models fit using WinBUGS 
software.  Some of the prior distributions presented the paper are weakly informative 
versions of the other prior distributions presented in that they give zero density to 
implausibly large values and do not allow unrealistically large values to be sampled.  
These weakly informative prior distributions are presented to show how estimates can 
change when unrealistically large values cannot be sampled.  We consider some of the 
prior distributions presented by Lambert et al (2005) for the scale parameters of the 
random effects in the mixed effects Bayesian models for bioequivalence presented 
earlier. 
Since precisionvariancedeviation standard /1    == , the prior distribution for 
the scale parameters of the random effects in the Bayesian models can be put on the 
variance, standard deviation, or precision.  The parameter that receives the prior 
distribution is found stochastically while the other two parameters are found 
deterministically.  For example, if the prior distribution is put on the variance parameter, 
then the standard deviation and precision parameters are found deterministically and the 
variance parameter is found stochastically.  Thirteen different prior distributions were 
used for the scale parameters of the random effects in the two Bayesian models presented 
above.  If we let σ represent the inter-subject and intra-subject standard deviation from 
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the two Bayesian models for bioequivalence presented above, then the thirteen prior 
distributions are as follows: 
Prior 1: 0.001) ,001.0(~12 Gammaσ  
Gamma (0.001, 0.001) on the Precision parameters is approximately uniform for most of 
its range, with a “spike” of probability mass close to zero. 
Prior 2: 0.1) ,1.0(~12 Gammaσ  
Gamma (0.1, 0.1) on the Precision parameters has the same distributional form of Prior 1, 
but with the two parameters set to 0.1 to assess the sensitivity to the choice of parameter 
values. 
Prior 3: 10) ,10(~)log( 2 −Uniformσ  
This prior distribution is uniform between –10 and 10 on the log variance scale of the 
variance parameters. 
Prior 4: 1.386) ,10(~)log( 2 −Uniformσ  
This prior distribution is a weakly informative version of Prior 3, but only goes to a 
maximum of log(4.0) = 1.386.  Although the choice for this upper bound is subjective 
and depends upon the particular analysis being considered, the rationale for the value of 
this upper bound is that it would seem doubtful that the inter-subject and intra-subject 
variances could have a value greater than four. 
Prior 5: 1000) ,001.0(~2 Uniformσ  




Prior 6: 4) ,001.0(~2 Uniformσ  
This prior distribution is a weakly informative version of Prior 5.  The choice for the 
upper bound value of 4 for this prior follows the same rationale given for the choice of 
the upper bound in Prior 4.  
Prior 7: 0.001) ,1(~12 Paretoσ   
This Pareto prior distribution from 1 to 0.001 on the precision parameters is equivalent to 
a uniform distribution from 0 to 1000 on the variance parameters. 
Prior 8: 0.25) ,1(~12 Paretoσ  
This prior distribution is a weakly informative version of Prior 7.  This prior distribution 
is equivalent to a uniform prior distribution from 0 to 4 on the variance parameters, or 
from 0 to 2 on the standard deviation parameters. 
Prior 9: 100) ,0(~ Uniformσ  
This prior distribution is uniform from 0 to 100 on the standard deviation parameters. 
Prior 10: 2) ,0(~ Uniformσ  
This prior distribution is a weakly informative version of Prior 9. 
Prior 11: 100) ,0(~ Normalσ  
This prior places a half-normal distribution from 0 to 100 on the standard deviation 
parameters. 
Prior 12: 1) ,0(~ Normalσ  




Prior 13:  Diffuse Priors Presented in Original Papers 
For the Bayesian model for ABE and PBE presented in the paper by Erickson, Seaman, 
and Stamey, Gamma (0.01, 0.01) prior distributions were placed on the inter-subject and 
intra-subject precision parameters.  For the Bayesian model for IBE presented by Ghosh 
and Ntzoufras, Gamma (0.0001, 0.0001) prior distributions were placed on the inter-





5.  RESULTS 
5.1.  Average and Population Bioequivalence 
The scale parameters of the random effects in the Bayesian Model for assessing 
average and population bioequivalence are tested on the prior distributions presented by 
Lambert et al (2005).  We consider three different data sets to test this model.  The first 
data set described by Chow and Liu (2000), is a 2×2 un-replicated crossover experiment 
with 24 subjects.  The second data set is drug 8 from the FDA’s website 
(http://www.fda.gov/cder/bioequivdata.), and is a 4×4 (two-period replicated) crossover 
experiment.  The third data set is drug 14c from the FDA’s website, and is a 2×4 
crossover design.  To analyze these data sets we use five parallel chains with 10,000 
burn-in iterations and 20,000 updates as suggested by the paper by Erickson, Seaman, 
and Stamey. 
For the 2×2 crossover data described by Chow and Liu (2000), Figure 1 shows the 
medians and 95 percent credible intervals for inter-subject variance, intra-subject 
variance, and population variance for each prior distribution and Table 1.A shows the 
results.  We see in Table 1.A that the two drugs described in the Chow and Liu data 
would be declared Average Bioequivalent under all thirteen prior distributions, and 
would not be declared population or Joint-Average-and-Population Bioequivalent under 
all thirteen prior distributions.  We see that Priors 2, 3, and 4 have the largest deviation 
from the original diffuse priors for Population Bioequivalence and Joint-Average-and-
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Population Bioequivalence.  For the variance parameters, Priors 2, 5, 6, 7, and 8 have the 
largest deviation from the original diffuse priors.     
For the 4×4 crossover data of drug 8, Figure 2 shows the medians and 95 percent 
credible intervals for inter-subject variance, intra-subject variance, and population 
variance for each prior distribution and Table 2.A shows the results.  We see in Table 2.A 
that these two drugs would be declared Average Bioequivalent but not Population or 
Joint-Average-and-Population Bioequivalent.  Prior 2 gives the largest deviation from the 
original diffuse priors for Population and Joint-Average-and-Population Bioequivalence.   
For the 2×4 crossover data of drug 14c, Figure 3 shows the medians and 95 
percent credible intervals for inter-subject variance, intra-subject variance, and 
population variance for each prior distribution and Table 3.A shows the results.  We see 
that the drugs described by this data would be declared Average, Population and Joint-
Average-and-Population Bioequivalent.   
Figures 1, 2, and 3 all show how the credible intervals differ for each prior 
distribution on the scale parameters.  The differing credible intervals could influence the 
inference.  Table 1.B, Table 2.B, and Table 3.B show the Percent Deviation of the first 
twelve priors to the diffuse priors presented in the original papers (prior 13).  These tables 
show how the population bioequivalence (PRV) and “joint-average-and-population” 
bioequivalence (PJT) inference is changing for each prior distribution on the scale 
parameters.  We see from these tables that the percent deviation on the average 
bioequivalence (PAB) inference is relatively small because average bioequivalence is not 
a function of variance.  The bioequivalence inference drawn from the data of drug 14c 
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was the least affected, and the bioequivalence inference drawn from the Chow and Liu 
data was most affected by changing the prior distribution on the scale parameters. 
Figure 4, Figure 5, and Figure 6 show the posterior densities of the variance 
parameters for prior distributions 1, 3, 5, 9, and 11 for the Chow and Liu data, FDA drug 
8 data, and FDA drug 14c data respectively.  These figures show the various prior 
distributions on the scale parameters can change the shape of the posterior distribution. 
Table 4, Table 5, and Table 6 shows the Deviance Information Criterion (DIC) for 




FIGURE 1:  Figure 1 above shows the medians and 95 percent credible intervals for 
inter-subject variance, intra-subject variance, and population variance obtained 
using the model in (1) on the data described by Chow and Liu for each prior 
distribution on the scale parameters. 
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FIGURE 2:  Figure 2 above shows the medians and 95 percent credible intervals for 
inter-subject variance, intra-subject variance, and population variance obtained 




FIGURE 3:  Figure 3 above shows the medians and 95 percent credible intervals for 
inter-subject variance, intra-subject variance, and population variance obtained 
using the model in (1) on the FDA drug 14c data for each prior distribution on the 
scale parameters. 
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TABLE 1.A:  Table 1.A below shows the estimated values using the disaggregate 
methodology for assessing average bioequivalence, population bioequivalence, joint 
average and population bioequivalence, population means, inter-subject variance, 
intra-subject variances, and population variances for the Chow and Liu data for 
each prior distribution on the scale parameters. 
 
 Parameter Prior 1 Prior 2 Prior 3 Prior 4 Prior 5 Prior 6 Prior 7 
PAB 0.9984 0.9963 0.9982 0.9981 0.9968 0.9967 0.997 
PJT 0.6122 0.7764 0.5478 0.5504 0.6387 0.6341 0.6406 
PRV 0.6129 0.7788 0.5486 0.5514 0.6402 0.6357 0.642 
µR 4.38 4.38 4.38 4.38 4.38 4.38 4.38 
µT 4.351 4.351 4.351 4.351 4.351 4.351 4.351 
2
γσ  0.04607 0.0578 0.04819 0.04836 0.05241 0.05254 0.05242 
2
Rσ  0.08979 0.1146 0.09385 0.09366 0.1029 0.1035 0.1027 
2
eRσ  0.04372 0.05681 0.04566 0.0453 0.05046 0.05094 0.0503 
2
Tσ  0.0906 0.1148 0.09217 0.09184 0.1034 0.1031 0.1034 
2
eTσ  0.04453 0.057 0.04398 0.04348 0.051 0.05057 0.05097 
 Parameter Prior 8 Prior 9 Prior 10 Prior 11 Prior 12 Prior 13  
PAB 0.9967 0.9976 0.998 0.9981 0.9979 0.9985  
PJT 0.6366 0.624 0.6117 0.6187 0.6203 0.672  
PRV 0.638 0.6251 0.6127 0.6196 0.6214 0.6727  
µR 4.379 4.38 4.379 4.38 4.38 4.38  
µT 4.351 4.351 4.351 4.351 4.351 4.351  
2
γσ  0.05216 0.04879 0.04909 0.04902 0.04825 0.04595  
2
Rσ  0.103 0.09593 0.09581 0.09594 0.09495 0.09019  
2
eRσ  0.05085 0.04714 0.04672 0.04692 0.04671 0.04424  
2
Tσ  0.103 0.0965 0.09693 0.09591 0.09594 0.09109  
2
eTσ  0.05085 0.04772 0.04784 0.04689 0.04769 0.04514  
 
 In Table 1.A we see that since PAB ≥ 0.90 for all prior distributions, then ABE 
inference is not affected by changing the prior distribution on the scale parameters.  In 
Table 1.B we see that changing the prior distribution on the scale parameters does cause 
large percent deviation from the original diffuse priors for PJT and PRV, however, since 
PJT < 0.90 and PRV < 0.90 for all thirteen prior distributions, then PBE and joint ABE 
and PBE inference is not affected.  
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TABLE 1.B:  Table 1.B below shows the percent deviation of the first twelve priors to 
the diffuse priors presented in the original papers (prior 13) for the results in Table 
1.A. 
 
 Parameter Prior 1 Prior 2 Prior 3 Prior 4 Prior 5 Prior 6 Prior 7 
PAB 0.01% 0.22% 0.03% 0.04% 0.17% 0.18% 0.15% 
PJT 8.90% 15.54% 18.48% 18.10% 4.96% 5.64% 4.67% 
PRV 8.89% 15.77% 18.45% 18.03% 4.83% 5.50% 4.56% 
µR 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 
µT 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 
2
γσ  0.26% 25.79% 4.87% 5.24% 14.06% 14.34% 14.08% 
2
Rσ  0.44% 27.07% 4.06% 3.85% 14.09% 14.76% 13.87% 
2
eRσ  1.18% 28.41% 3.21% 2.40% 14.06% 15.14% 13.70% 
2
Tσ  0.54% 26.03% 1.19% 0.82% 13.51% 13.18% 13.51% 
2
eTσ  1.35% 26.27% 2.57% 3.68% 12.98% 12.03% 12.92% 
 Parameter Prior 8 Prior 9 Prior 10 Prior 11 Prior 12 Prior 13  
PAB 0.18% 0.09% 0.05% 0.04% 0.06% -  
PJT 5.27% 7.14% 8.97% 7.93% 7.69% -  
PRV 5.16% 7.08% 8.92% 7.89% 7.63% -  
µR 0.02% 0.00% 0.02% 0.00% 0.00% -  
µT 0.00% 0.00% 0.00% 0.00% 0.00% -  
2
γσ  13.51% 6.18% 6.83% 6.68% 5.01% -  
2
Rσ  14.20% 6.36% 6.23% 6.38% 5.28% -  
2
eRσ  14.94% 6.56% 5.61% 6.06% 5.58% -  
2
Tσ  13.07% 5.94% 6.41% 5.29% 5.32% -  
2





TABLE 2.A:  Table 2.A below shows the estimated values using the disaggregate 
methodology for assessing average bioequivalence, population bioequivalence, joint 
average and population bioequivalence, population means, inter-subject variance, 
intra-subject variances, and population variances for the FDA drug 8 data for each 
prior distribution on the scale parameters. 
 
 Parameter Prior 1 Prior 2 Prior 3 Prior 4 Prior 5 Prior 6 Prior 7 
PAB 0.9998 0.9995 0.9997 0.9998 0.9996 0.9996 0.9996 
PJT 0.8127 0.8691 0.8131 0.8135 0.8266 0.8273 0.8308 
PRV 0.8128 0.8694 0.8133 0.8137 0.8269 0.8275 0.831 
µR 7.598 7.598 7.598 7.598 7.598 7.598 7.598 
µT 7.605 7.605 7.605 7.606 7.605 7.606 7.605 
2
γσ  0.05631 0.0769 0.05586 0.05597 0.07146 0.07173 0.07208 
2
Rσ  0.1206 0.1469 0.12 0.1201 0.1403 0.1403 0.1404 
2
eRσ  0.06427 0.06995 0.06412 0.06417 0.06888 0.0686 0.06835 
2
Tσ  0.1151 0.1419 0.1147 0.1148 0.1344 0.1347 0.1353 
2
eTσ  0.05877 0.06503 0.0588 0.05879 0.06292 0.06293 0.06321 
 Parameter Prior 8 Prior 9 Prior 10 Prior 11 Prior 12 Prior 13  
PAB 0.9996 0.9997 0.9997 0.9997 0.9998 0.9998  
PJT 0.8301 0.8187 0.8226 0.8206 0.8228 0.8217  
PRV 0.8304 0.8189 0.8228 0.8208 0.823 0.8218  
µR 7.598 7.598 7.598 7.598 7.598 7.598  
µT 7.605 7.605 7.605 7.605 7.606 7.605  
2
γσ  0.07264 0.06345 0.06361 0.06326 0.06271 0.05883  
2
Rσ  0.1414 0.1298 0.1299 0.1296 0.1286 0.1234  
2
eRσ  0.06873 0.06635 0.06629 0.06637 0.06588 0.06456  
2
Tσ  0.1354 0.1243 0.1244 0.1239 0.1235 0.1181  
2
eTσ  0.06272 0.06081 0.06076 0.06063 0.06084 0.05922  
 
 
 In Table 2.A we see that PAB ≥ 0.90 for all prior distributions, thus the ABE 
inference is not affected by changing the prior distribution on the scale parameters.  Since 
PJT < 0.90 and PRV < 0.90 for all thirteen prior distributions, then PBE and joint ABE 
and PBE inference is not affected here either.  The two drugs described by this data 
would be declared Average Bioequivalent, but would not be declared Population 
Bioequivalent or Joint-Average-and-Population Bioequivalent for all thirteen prior 
distributions on the scale parameters. 
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TABLE 2.B:  Table 2.B below shows the percent deviation of the first twelve priors to 
the diffuse priors presented in the original papers (prior 13) for the results in Table 
2.A. 
 
 Parameter Prior 1 Prior 2 Prior 3 Prior 4 Prior 5 Prior 6 Prior 7 
PAB 0.00% 0.03% 0.01% 0.00% 0.02% 0.02% 0.02% 
PJT 1.10% 5.77% 1.05% 1.00% 0.60% 0.68% 1.11% 
PRV 1.10% 5.79% 1.03% 0.99% 0.62% 0.69% 1.12% 
µR 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 
µT 0.00% 0.00% 0.00% 0.01% 0.00% 0.01% 0.00% 
2
γσ  4.28% 30.72% 5.05% 4.86% 21.47% 21.93% 22.52% 
2
Rσ  2.27% 19.04% 2.76% 2.67% 13.70% 13.70% 13.78% 
2
eRσ  0.45% 8.35% 0.68% 0.60% 6.69% 6.26% 5.87% 
2
Tσ  2.54% 20.15% 2.88% 2.79% 13.80% 14.06% 14.56% 
2
eTσ  0.76% 9.81% 0.71% 0.73% 6.25% 6.26% 6.74% 
 Parameter Prior 8 Prior 9 Prior 10 Prior 11 Prior 12 Prior 13  
PAB 0.02% 0.01% 0.01% 0.01% 0.00% -  
PJT 1.02% 0.37% 0.11% 0.13% 0.13% -  
PRV 1.05% 0.35% 0.12% 0.12% 0.15% -  
µR 0.00% 0.00% 0.00% 0.00% 0.00% -  
µT 0.00% 0.00% 0.00% 0.00% 0.01% -  
2
γσ  23.47% 7.85% 8.13% 7.53% 6.60% -  
2
Rσ  14.59% 5.19% 5.27% 5.02% 4.21% -  
2
eRσ  6.46% 2.77% 2.68% 2.80% 2.04% -  
2
Tσ  14.65% 5.25% 5.33% 4.91% 4.57% -  
2





TABLE 3.A:  Table 3.A below shows the estimated values using the disaggregate 
methodology for assessing average bioequivalence, population bioequivalence, joint 
average and population bioequivalence, population means, inter-subject variance, 
intra-subject variances, and population variances for the FDA drug 14c data for 
each prior distribution on the scale parameters. 
 
 Parameter Prior 1 Prior 2 Prior 3 Prior 4 Prior 5 Prior 6 Prior 7 
PAB 1 1 1 1 1 1 1 
PJT 0.9945 0.9973 0.9942 0.9942 0.9948 0.9942 0.9948 
PRV 0.9945 0.9973 0.9942 0.9942 0.9948 0.9942 0.9948 
µR 5.613 5.613 5.613 5.613 5.613 5.613 5.613 
µT 5.599 5.599 5.599 5.599 5.599 5.6 5.6 
2
γσ  0.04611 0.05154 0.04606 0.04609 0.04948 0.04953 0.04957 
2
Rσ  0.06148 0.07096 0.06141 0.06148 0.06544 0.06545 0.06552 
2
eRσ  0.01537 0.01942 0.01535 0.01539 0.01597 0.01592 0.01595 
2
Tσ  0.06734 0.07582 0.06724 0.06722 0.07143 0.07154 0.07154 
2
eTσ  0.02123 0.02428 0.02119 0.02113 0.02195 0.02201 0.02197 
 Parameter Prior 8 Prior 9 Prior 10 Prior 11 Prior 12 Prior 13  
PAB 1 1 1 1 1 1  
PJT 0.9946 0.9944 0.9943 0.9945 0.9947 0.9949  
PRV 0.9946 0.9944 0.9943 0.9945 0.9947 0.9949  
µR 5.613 5.613 5.613 5.613 5.613 5.613  
µT 5.599 5.599 5.599 5.599 5.599 5.6  
2
γσ  0.04936 0.04776 0.04775 0.04779 0.04773 0.04665  
2
Rσ  0.0653 0.0634 0.06342 0.06342 0.06336 0.06245  
2
eRσ  0.01593 0.01564 0.01567 0.01564 0.01564 0.0158  
2
Tσ  0.07133 0.06934 0.06934 0.06933 0.06927 0.06811  
2
eTσ  0.02197 0.02157 0.02159 0.02154 0.02155 0.02146  
 
 
 In Table 3.A we see that PAB ≥ 0.90, PJT ≥ 0.90, and PRV ≥ 0.90 for all prior 
distributions, thus the ABE, PBE, and Joint-ABE-and-PBE inference is not affected by 
changing the prior distribution on the scale parameters.   
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TABLE 3.B:  Table 3.B below shows the percent deviation of the first twelve priors to 
the diffuse priors presented in the original papers (prior 13) for the results in Table 
3.A. 
 
 Parameter Prior 1 Prior 2 Prior 3 Prior 4 Prior 5 Prior 6 Prior 7 
PAB 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 
PJT 0.04% 0.24% 0.07% 0.07% 0.01% 0.07% 0.01% 
PRV 0.04% 0.24% 0.07% 0.07% 0.01% 0.07% 0.01% 
µR 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 
µT 0.02% 0.02% 0.02% 0.02% 0.02% 0.00% 0.00% 
2
γσ  1.16% 10.48% 1.26% 1.20% 6.07% 6.17% 6.26% 
2
Rσ  1.55% 13.63% 1.67% 1.55% 4.79% 4.80% 4.92% 
2
eRσ  2.72% 22.91% 2.85% 2.59% 1.08% 0.76% 0.95% 
2
Tσ  1.13% 11.32% 1.28% 1.31% 4.87% 5.04% 5.04% 
2
eTσ  1.07% 13.14% 1.26% 1.54% 2.28% 2.56% 2.38% 
 Parameter Prior 8 Prior 9 Prior 10 Prior 11 Prior 12 Prior 13  
PAB 0.00% 0.00% 0.00% 0.00% 0.00% -  
PJT 0.03% 0.05% 0.06% 0.04% 0.02% -  
PRV 0.03% 0.05% 0.06% 0.04% 0.02% -  
µR 0.00% 0.00% 0.00% 0.00% 0.00% -  
µT 0.02% 0.02% 0.02% 0.02% 0.02% -  
2
γσ  5.81% 2.38% 2.36% 2.44% 2.32% -  
2
Rσ  4.56% 1.52% 1.55% 1.55% 1.46% -  
2
eRσ  0.82% 1.01% 0.82% 1.01% 1.01% -  
2
Tσ  4.73% 1.81% 1.81% 1.79% 1.70% -  
2







FIGURE 4:  Figure 4 above shows posterior distributions of the variance parameters 
obtained using the model in (1) on the Chow and Liu data for prior distributions 1, 




FIGURE 5:  Figure 5 above shows posterior distributions of the variance parameters 
obtained using the model in (1) on the FDA drug 8 data for prior distributions 1, 3, 




FIGURE 6:  Figure 6 above shows posterior distributions of the variance parameters 
obtained using the model in (1) on the FDA drug 14c data for prior distributions 1, 
3, 5, 9, and 11 on the scale parameters. 
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TABLE 4:  Table 4 below shows the WinBUGS Deviance Information Criterion 
(DIC) for the model in (1) on the Chow and Liu data. 
Dbar = post.mean of -2logL; Dhat = -2LogL at post.mean of stochastic nodes 
  
Dbar   Dhat   pD   DIC 
  
z -285.534  -515.809  230.275  -55.260 
  
total -277.217  -507.491  230.275  -46.942  
 
TABLE 5:  Table 5 below shows the WinBUGS Deviance Information Criterion 
(DIC) for the model in (1) on the FDA drug 8 data. 
 
Dbar = post.mean of -2logL; Dhat = -2LogL at post.mean of stochastic nodes 
  
Dbar   Dhat   pD   DIC  
 
z 2.386   -275.606  277.992  280.378 
  
total 10.704   -267.289  277.992  288.696  
 
TABLE 6:  Table 6 below shows the WinBUGS Deviance Information Criterion 
(DIC) for the model in (1) on the FDA drug 14c data. 
 
Dbar = post.mean of -2logL; Dhat = -2LogL at post.mean of stochastic nodes 
 
 Dbar   Dhat   pD   DIC  
 
z -2353.300  -2878.040  524.738  -1828.560  
  
total -2344.980  -2869.720  524.738  -1820.240  
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5.2.  Individual Bioequivalence 
The scale parameters of the random effects in the Bayesian Model for assessing 
individual bioequivalence presented by Ghosh and Ntzoufras are tested on the prior 
distributions presented by Lambert et al.  We consider two different data sets to test this 
model.  The first data set is drug 8 from the FDA’s website.  The second data set is drug 
14c from the FDA’s website.  Since each treatment immediately precedes every other 
treatment the same number of times in the data of drug 14c, this data set is balanced with 
respect to first-order carry-over effects.  Thus, the data of drug 14c is also used to 
examine the change in the common carry-over effect λ as the prior distributions change 
on the variance parameters. To analyze these data sets we use 1,000 burn-in iterations and 
10,000 updates as suggested by the paper by Ghosh and Ntzoufras. 
The model in (2) was used to aggregately assess Individual Bioequivalence for the 
data of drug 8.  Figure 7 shows the medians and 95 percent credible intervals for inter-
subject variance, intra-subject variance, population variance, and subject-by-formulation 
interaction variance for each prior distribution and Table 7.A shows the results.  The 
model in (2) was also used to aggregately assess Individual Bioequivalence for the data 
of drug 14c, and Figure 8 shows the medians and 95 percent credible intervals for inter-
subject variance, intra-subject variance, population variance, and subject-by-formulation 
interaction variance for each prior distribution and Table 8.A shows the results.  Figures 7 
and 8 both show how the credible intervals differ for each prior distribution on the scale 
parameters.  Table 7.B and Table 8.B show the Percent Deviation of the first twelve 
priors to the diffuse priors presented in the original papers (prior 13).  These tables show 
how the Individual Bioequivalence inference (IBEH0) is changing for each prior 
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distribution on the scale parameters.  Figure 9 and Figure 10 show the posterior densities 
of the variance parameters for prior distributions 1, 3, 5, 9, and 11 for the FDA drug 8 
data, and FDA drug 14c data respectively.  Table 9 and Table 10 show the Deviance 
Information Criterion (DIC) for each prior distribution on the scale parameters of the 
model in (2) on the FDA drug 8 data and the FDA drug 14c data respectively. 
 The model in (3) was used on the data of drug 14c to examine the change the 
common carry-over effect λ.  Figure 11 shows the medians and 95 percent credible 
intervals for each λ obtained by changing the prior distributions on the variance 
parameters and Table 11 shows the results.  
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FIGURE 7:  Figure 7 above shows the medians and 95 percent credible intervals for 
inter-subject variance, intra-subject variance, and population variance obtained 




FIGURE 8:  Figure 8 above shows the medians and 95 percent credible intervals for 
inter-subject variance, intra-subject variance, and population variance obtained 
using the model in (2) on the FDA drug 14c data for each prior distribution on the 
scale parameters. 
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TABLE 7.A:  Table 7.A below shows the estimated values using the aggregate 
methodology for assessing Individual bioequivalence, population means, inter-
subject variances, intra-subject variances, population variances, subject-by-
formulation interaction variance, and correlation for the FDA drug 8 data for each 
prior distribution on the scale parameters. 
 
Parameter Prior 1 Prior 2 Prior 3 Prior 4 Prior 5 Prior 6 Prior 7 
ΘIBE 0.8901 1.164 0.8745 0.836 1.083 1.123 1.125 
IBEH0 0.91821 0.8733 0.91671 0.92611 0.8865 0.8745 0.8721 
2
BRσ  0.05732 0.09105 0.05193 0.05364 0.08049 0.08482 0.08731 
2
BTσ  0.06604 0.09393 0.06328 0.06168 0.09105 0.09187 0.09014 
2
Dσ  0.04919 0.06413 0.05055 0.04721 0.06301 0.06297 0.06387 
2
TRσ  0.1165 0.1554 0.1153 0.1154 0.1438 0.1475 0.1501 
2
TTσ  0.1075 0.1444 0.1056 0.1056 0.1357 0.1366 0.1348 
2
WRσ  0.05918 0.06431 0.06335 0.06175 0.06333 0.0627 0.06282 
2
WTσ  0.04144 0.05052 0.04237 0.04393 0.04468 0.04471 0.04467 
µT 7.465 7.464 7.458 7.471 7.463 7.474 7.466 
µR 7.507 7.513 7.513 7.516 7.507 7.52 7.509 
ρ 0.6416 0.6722 0.5928 0.6198 0.6579 0.661 0.6639 
Parameter Prior 8 Prior 9 Prior 10 Prior 11 Prior 12 Prior 13  
ΘIBE 1.158 1.046 1.031 1.026 1.042 0.9136  
IBEH0 0.8649 0.8926 0.8934 0.8965 0.8948 0.91231  
2
BRσ  0.08297 0.06666 0.06814 0.0676 0.06987 0.05666  
2
BTσ  0.09407 0.0753 0.07834 0.07743 0.07587 0.06597  
2
Dσ  0.06405 0.05806 0.05917 0.05802 0.05828 0.0521  
2
TRσ  0.145 0.127 0.129 0.1285 0.1296 0.118  
2
TTσ  0.1386 0.1173 0.12 0.1192 0.1181 0.1084  
2
WRσ  0.06205 0.06031 0.06086 0.06092 0.05978 0.06135  
2
WTσ  0.0445 0.04203 0.04166 0.0418 0.04228 0.04246  
µT 7.475 7.469 7.463 7.472 7.481 7.468  
µR 7.517 7.515 7.507 7.517 7.523 7.513  
ρ 0.667 0.6223 0.6252 0.6308 0.63 0.605  
 
 
 In Table 7.A we see that IBEH0 ≥ 0.90 for priors 1, 3, 4, and 13, and IBEH0 < 
0.90 for all other priors, thus, the Individual Bioequivalence inference is affected by 
changing the prior distribution of the scale parameters of the random effects for this data. 
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TABLE 7.B:  Table 7.B below shows the percent deviation of the first twelve priors to 
the diffuse priors presented in the original papers (prior 13) for the results in Table 
7.A.  We see that changing the prior distribution on the scale parameters of the 
random effects causes large percent deviations from the original diffuse priors. 
 
Parameter Prior 1 Prior 2 Prior 3 Prior 4 Prior 5 Prior 6 Prior 7 
ΘIBE 2.57% 27.41% 4.28% 8.49% 18.54% 22.92% 23.14% 
IBEH0 6.73% 44.49% 5.02% 15.74% 29.43% 43.12% 45.85% 
2
BRσ  1.16% 60.70% 8.35% 5.33% 42.06% 49.70% 54.09% 
2
BTσ  0.11% 42.38% 4.08% 6.50% 38.02% 39.26% 36.64% 
2
Dσ  5.59% 23.09% 2.98% 9.39% 20.94% 20.86% 22.59% 
2
TRσ  1.27% 31.69% 2.29% 2.20% 21.86% 25.00% 27.20% 
2
TTσ  0.83% 33.21% 2.58% 2.58% 25.18% 26.01% 24.35% 
2
WRσ  3.54% 4.82% 3.26% 0.65% 3.23% 2.20% 2.40% 
2
WTσ  2.40% 18.98% 0.21% 3.46% 5.23% 5.30% 5.20% 
µT 0.04% 0.05% 0.13% 0.04% 0.07% 0.08% 0.03% 
µR 0.08% 0.00% 0.00% 0.04% 0.08% 0.09% 0.05% 
ρ 6.05% 11.11% 2.02% 2.45% 8.74% 9.26% 9.74% 
Parameter Prior 8 Prior 9 Prior 10 Prior 11 Prior 12 Prior 13  
ΘIBE 26.75% 14.49% 12.85% 12.30% 14.05% -  
IBEH0 54.07% 22.48% 21.56% 18.03% 19.97% -  
2
BRσ  46.43% 17.65% 20.26% 19.31% 23.31% -  
2
BTσ  42.60% 14.14% 18.75% 17.37% 15.01% -  
2
Dσ  22.94% 11.44% 13.57% 11.36% 11.86% -  
2
TRσ  22.88% 7.63% 9.32% 8.90% 9.83% -  
2
TTσ  27.86% 8.21% 10.70% 9.96% 8.95% -  
2
WRσ  1.14% 1.70% 0.80% 0.70% 2.56% -  
2
WTσ  4.80% 1.01% 1.88% 1.55% 0.42% -  
µT 0.09% 0.01% 0.07% 0.05% 0.17% -  
µR 0.05% 0.03% 0.08% 0.05% 0.13% -  





TABLE 8.A:  Table 8.A below shows the estimated values using the aggregate 
methodology for assessing Individual bioequivalence, population means, inter-
subject variances, intra-subject variances, population variances, subject-by-
formulation interaction variance, and correlation for the FDA drug 14c data for 
each prior distribution on the scale parameters. 
 
Parameter Prior 1 Prior 2 Prior 3 Prior 4 Prior 5 Prior 6 Prior 7 
ΘIBE 0.01382 0.02506 0.02138 0.1336 0.002207 0.02325 0.01477 
IBEH0 1 1 1 0.9786 1 1 1 
2
BRσ  0.03586 0.04696 0.03602 0.1002 0.04105 0.06534 0.04148 
2
BTσ  0.05225 0.06322 0.05202 0.149 0.05786 0.08464 0.05833 
2
Dσ  0.007146 0.006364 0.007358 0.01095 0.006768 0.007216 0.007148 
2
TRσ  0.05637 0.07091 0.05647 0.1206 0.06229 0.08641 0.06262 
2
TTσ  0.06548 0.08108 0.06527 0.1623 0.07173 0.09863 0.07223 
2
WRσ  0.02051 0.02395 0.02044 0.0204 0.02124 0.02107 0.02114 
2
WTσ  0.01324 0.01786 0.01325 0.01326 0.01387 0.01399 0.0139 
µT 5.601 5.604 5.602 5.574 5.598 5.583 5.597 
µR 5.612 5.615 5.614 5.58 5.61 5.594 5.608 
ρ 0.9415 0.9589 0.9375 0.9414 0.9515 0.9506 0.9463 
Parameter Prior 8 Prior 9 Prior 10 Prior 11 Prior 12 Prior 13  
ΘIBE 0.01477 0.02267 0.01071 0.01297 0.01183 0.01128  
IBEH0 1 1 1 1 1 1  
2
BRσ  0.04148 0.03853 0.03725 0.03904 0.03859 0.03557  
2
BTσ  0.05833 0.05409 0.05377 0.05475 0.0548 0.05234  
2
Dσ  0.007148 0.00724 0.006946 0.006998 0.007061 0.007097  
2
TRσ  0.06262 0.05916 0.05805 0.05975 0.05934 0.05616  
2
TTσ  0.07223 0.0677 0.06738 0.06828 0.06828 0.06556  
2
WRσ  0.02114 0.02062 0.02081 0.02071 0.02074 0.02059  
2
WTσ  0.0139 0.01361 0.01362 0.01353 0.01349 0.01322  
µT 5.597 5.599 5.6 5.602 5.6 5.603  
µR 5.608 5.61 5.611 5.615 5.612 5.615  
ρ 0.9463 0.9409 0.9455 0.9435 0.9432 0.9428  
 
 
 In Table 7.A we see that IBEH0 ≥ 0.90 for all thirteen prior distributions, thus, the 
Individual Bioequivalence inference is not affected by changing the prior distribution of 
the scale parameters of the random effects for this data. 
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TABLE 8.B:  Table 8.B below shows the percent deviation of the first twelve priors to 
the diffuse priors presented in the original papers (prior 13) for the results in Table 
8.A. 
 
Parameter Prior 1 Prior 2 Prior 3 Prior 4 Prior 5 Prior 6 Prior 7 
ΘIBE 22.52% 122.16% 89.54% 1084.40% 80.43% 106.12% 30.94% 
IBEH0 0.00% 0.00% 0.00% 2.14% 0.00% 0.00% 0.00% 
2
BRσ  0.82% 32.02% 1.27% 181.70% 15.41% 83.69% 16.62% 
2
BTσ  0.17% 20.79% 0.61% 184.68% 10.55% 61.71% 11.44% 
2
Dσ  0.69% 10.33% 3.68% 54.29% 4.64% 1.68% 0.72% 
2
TRσ  0.37% 26.26% 0.55% 114.74% 10.92% 53.86% 11.50% 
2
TTσ  0.12% 23.67% 0.44% 147.56% 9.41% 50.44% 10.17% 
2
WRσ  0.39% 16.32% 0.73% 0.92% 3.16% 2.33% 2.67% 
2
WTσ  0.15% 35.10% 0.23% 0.30% 4.92% 5.82% 5.14% 
µT 0.04% 0.02% 0.02% 0.52% 0.09% 0.36% 0.11% 
µR 0.05% 0.00% 0.02% 0.62% 0.09% 0.37% 0.12% 
ρ 0.14% 1.71% 0.56% 0.15% 0.92% 0.83% 0.37% 
Parameter Prior 8 Prior 9 Prior 10 Prior 11 Prior 12 Prior 13  
ΘIBE 30.94% 100.98% 5.05% 14.98% 4.88% -  
IBEH0 0.00% 0.00% 0.00% 0.00% 0.00% -  
2
BRσ  16.62% 8.32% 4.72% 9.76% 8.49% -  
2
BTσ  11.44% 3.34% 2.73% 4.60% 4.70% -  
2
Dσ  0.72% 2.01% 2.13% 1.39% 0.51% -  
2
TRσ  11.50% 5.34% 3.37% 6.39% 5.66% -  
2
TTσ  10.17% 3.26% 2.78% 4.15% 4.15% -  
2
WRσ  2.67% 0.15% 1.07% 0.58% 0.73% -  
2
WTσ  5.14% 2.95% 3.03% 2.34% 2.04% -  
µT 0.11% 0.07% 0.05% 0.02% 0.05% -  
µR 0.12% 0.09% 0.07% 0.00% 0.05% -  





FIGURE 9:  Figure 9 above shows posterior distributions of the variance parameters 
obtained using the model in (2) on the FDA drug 8 data for prior distributions 1, 3, 
5, 9, and 11 on the scale parameters. 
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FIGURE 10:  Figure 10 above shows posterior distributions of the variance 
parameters obtained using the model in (2) on the FDA drug 14c data for prior 
distributions 1, 3, 5, 9, and 11 on the scale parameters. 
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TABLE 9:  Table 9 below shows the Deviance Information Criterion (DIC) for each 
prior distribution on the scale parameters for the model in (2) on the FDA drug 8 
data. 
 
    Dbar Dhat pD DIC 
Prior 1 z -18.346 -57.117 38.77 20.424 
  
total -18.346 -57.117 38.77 20.424 
Prior 2 z -13.935 -53.332 39.398 25.463 
  
total -13.935 -53.332 39.398 25.463 
Prior 3 z -15.96 -51.904 35.944 19.984 
  
total -15.96 -51.904 35.944 19.984 
Prior 4 z -15.666 -51.357 35.691 20.026 
  
total -15.666 -51.357 35.691 20.026 
Prior 5 z -16.924 -51.236 34.312 17.388 
  
total -16.924 -51.236 34.312 17.388 
Prior 6 z -17.269 -51.528 34.258 16.989 
  
total -17.269 -51.528 34.258 16.989 
Prior 7 z -17.281 -57.659 40.378 23.097 
  
total -17.281 -57.659 40.378 23.097 
Prior 8 z -17.624 -57.85 40.226 22.602 
  
total -17.624 -57.85 40.226 22.602 
Prior 9 z -19.049 -54.574 35.525 16.475 
  
total -19.049 -54.574 35.525 16.475 
Prior 10 z -18.813 -54.478 35.665 16.852 
  
total -18.813 -54.478 35.665 16.852 
Prior 11 z -18.685 -54.29 35.604 16.919 
  
total -13.14 -48.745 35.604 22.464 
Prior 12 z -18.959 -54.75 35.79 16.831 
  
total -13.414 -49.204 35.79 22.376 
Prior 13 z -16.866 -56.044 39.178 22.312 
  
total -16.866 -56.044 39.178 22.312 
 
 Deviance Information Criteria or DIC is used for model selection and determining 
the sensitivity of the results to the prior specification.  DIC is the Bayesian equivalent to 
AIC.  DIC = Dbar+pD where small values of Dbar indicate that the model fits the data 
and pD measures the complexity of the model.  In the table above we see that Prior 9, 
which has a Uniform distribution, has the best DIC, and is therefore better in this case 
than the inverse gamma distribution on the variance parameters. 
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TABLE 10:  Table 10 below shows the Deviance Information Criterion (DIC) for 
each prior distribution on the scale parameters of the model in (2) on the FDA drug 
14c data. 
 
    Dbar Dhat pD DIC 
Prior 1 z -196.576 -248.332 51.757 -144.819 
  
total -196.576 -248.332 51.757 -144.819 
Prior 2 z -181.451 -231.217 49.766 -131.684 
  
total -181.451 -231.217 49.766 -131.684 
Prior 3 z -196.619 -247.739 51.12 -145.5 
  
total -196.619 -247.739 51.12 -145.5 
Prior 4 z -196.783 -247.911 51.128 -145.655 
  
total -196.783 -247.911 51.128 -145.655 
Prior 5 z -193.95 -242.954 49.005 -144.945 
  
total -193.95 -242.954 49.005 -144.945 
Prior 6 z -194.098 -243.575 49.477 -144.62 
  
total -194.098 -243.575 49.477 -144.62 
Prior 7 z -194.371 -246.423 52.052 -142.318 
  
total -194.371 -246.423 52.052 -142.318 
Prior 8 z -194.371 -246.423 52.052 -142.318 
  
total -194.371 -246.423 52.052 -142.318 
Prior 9 z -195.73 -246.156 50.427 -145.303 
  
total -195.73 -246.156 50.427 -145.303 
Prior 10 z -195.102 -244.785 49.683 -145.42 
  
total -195.102 -244.785 49.683 -145.42 
Prior 11 z -195.653 -245.8 50.147 -145.505 
  
total -190.108 -240.255 50.147 -139.96 
Prior 12 z -195.841 -246.059 50.218 -145.623 
  
total -190.296 -240.514 50.218 -140.078 
Prior 13 z -196.333 -248.013 51.68 -144.653 
  



























FIGURE 11:  Figure 11 above shows the medians and 95 percent credible intervals 
for the common carry-over effect λ obtained using the model in (3) on the FDA drug 
14c data for each prior distribution on the scale parameters. 
 
TABLE 11:  Table 11 below shows the estimated values, standard deviation, median, 
and 95% credible interval for the common carry-over effect λ obtained using the 
model in (3) on the FDA drug 14c data for each prior distribution on the scale 
parameters. 
 
  Common Carry-over effect λ 
Prior mean sd 5.0% median 95.0% 
1 5.641 0.5223 4.914 5.608 6.65 
2 6.364 0.5575 5.731 6.235 7.564 
3 7.654 0.5449 6.439 7.715 8.403 
4 7.212 0.9108 5.891 7.117 8.794 
5 7.212 0.9108 5.891 7.117 8.794 
6 3.834 0.8588 2.811 3.455 5.387 
7 3.867 0.83 2.949 3.544 5.574 
8 6.602 0.4638 5.895 6.556 7.414 
9 7.881 1.074 6.039 8.324 9.144 
10 6.07 0.3742 5.361 6.094 6.62 
11 7.989 1.051 6.488 8.142 9.653 
12 6.687 0.4846 5.987 6.605 7.539 




6.  DISCUSSION 
We have assessed the performance of several different models for determining 
Bioequivalence by changing the prior distribution on the variance parameters.  We used 
thirteen different prior distributions for the variance parameters.  Three data sets were 
used for our assessment.  We also examined the effect that changing the prior distribution 
on the variance parameters had on the IBE model with and without the assumption of a 
carry-over effect. 
For the disaggregate model for determining ABE and PBE, Prior 2 consistently 
gave the largest deviation from the original diffuse priors for the estimates of the variance 
parameters as well as Population Bioequivalence for the three data sets examined.  The 
model estimates on the FDA drug 14c data were least affected and the model estimates 
on the Chow and Liu data were most affected by changing the prior distribution of the 
variance parameters. 
For the aggregate model for determining IBE with no carry-over effect, Prior 2 
and Prior 6 tended to give the largest deviation from the original diffuse priors for the 
variance parameters as well as IBE.  For the two data sets examined for this model, the 
within-subject variances were least affected by changing the prior distribution on the 
variance parameters.  In examining the DIC, we see that for the FDA drug 8 data, Prior 9 
has the best DIC.  For the FDA drug 14c data we see that there is no prior that clearly has 
a better DIC than another.  For the aggregate model for determining IBE with carry-over 
effect, we see that the carry-over parameter is most sensitive to Prior 6 and Prior 7. 
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A.1.  WinBUGS Code for Average and Population Bioequivalence 
 
A.1.0.  Prior Distributions 
 
#---------------------------------------------------------- 










































# PRIOR 3 - UNIFORM(-10,10) ON LOG VARIANCE 
#------------------------------------------- 
lvis[3] ~ dunif(-10,10) 
lvr[3] ~ dunif(-10,10) 
















# PRIOR 4 - UNIFORM(-10,4) ON LOG VARIANCE 
#------------------------------------------- 
lvis[4] ~ dunif(-10,4) 
lvr[4] ~ dunif(-10,4) 















# PRIOR 5 - UNIFORM(0, 1000) ON VARIANCE 
#----------------------------------------- 
rvar[5] ~ dunif(0,1000) 
tvar[5] ~ dunif(0,1000) 















# PRIOR 6 - UNIFORM(0, 4) ON VARIANCE 
#----------------------------------------- 
rvar[6] ~ dunif(0,4) 
tvar[6] ~ dunif(0,4) 
















# PRIOR 7 - PARETO(1,0.001) ON PRECISION 
#----------------------------------------- 
 
tau1[7] ~ dpar(1,0.001) 
tau2[7] ~ dpar(1,0.001) 















# PRIOR 8 - PARETO(1,0.25) ON PRECISION 
#----------------------------------------- 
 
tau1[8] ~ dpar(1, 0.1) 
tau2[8] ~ dpar(1, 0.1) 


























sdr[9] ~ dunif(0,100) 
sdt[9] ~ dunif(0,100) 



















sdr[10] ~ dunif(0,2) 
sdt[10] ~ dunif(0,2) 


















sdr[11] ~ dnorm(0,0.01)I(0,) 
sdt[11] ~ dnorm(0,0.01)I(0,) 


















sdr[12] ~ dnorm(0,1)I(0,) 
sdt[12] ~ dnorm(0,1)I(0,) 



























A.1.1.  ABE and PBE WinBUGS code for Chow and Liu Data 
 
#BAYESIAN METHODS FOR BIOEQUIVALENCE ALENCES STUDIES 
#CODE FOR MODELS I1 USING cHOW AND LIU DATA ON 13 PRIORS 
 
#alpha is a common intercept parameter 
#x[i,1] are the sequence indicators 
#x[i,2] are the period indicators 
#x[i,3] is treatment indicator 
#s[g[i]] corresponds to the random subject (sequence) effect 
#g[i] is a variable that assigns a common subject number to each set of 





for (m in 1:13){ 
 










for (k in 1:24){ 
 s[k,m]~dnorm (alpha[m],tau3[m])  
 } 
 













#Here we calculate the probability of equivalence in means, equivalence 






#The fixed effects parameters get diffuse normal prior distributions 












#  PRIOR DISTRIBUTIONS ON SCALE PARAMETERS 
#---------------------------------------------------------- 







list(alpha = c(0,0,0,0,0,0,0,0,0,0,0,0,0), 
beta=structure(.Data=c(0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,
0,0,0,0,0,0,0,0,0,0,0,0,0,0,0),.Dim=c(3,13)), tau1 = 
c(1,1,NA,NA,NA,NA,1,1,NA,NA,NA,NA,1), tau2 =  












A.1.2.  ABE and PBE WinBUGS Code for FDA Drug 8 Data 
 
#BAYESIAN METHODS FOR BIOEQUIVALENCE ALENCES STUDIES 
#CODE FOR MODELS I1 USING FDA DRUG 8 DATA ON 13 PRIORS 
 
#alpha is a common intercept parameter 
#x[i,1]-x[i,3] are the sequence indicators 
#x[i,4]-x[i,6] are the period indicators 
#x[i,7] is treatment indicator 
#s[g[i]] corresponds to the random subject (sequence) effect 
#g[i] is a variable that assigns a common subject number to each set of 





for (m in 1:13){ 
 







for (i in 39:N){ 
z[i,m]<-log(y[i]) 





for (k in 1:19){ 
 s[k,m]~dnorm (alpha[m],tau3[m])  #assumption of normal 
random subject effects 
 } 
 














#Here we calculate the probability of equivalence in means, equivalence 






#The fixed effects parameters get diffuse normal prior distributions 
















#  PRIOR DISTRIBUTIONS ON SCALE PARAMETERS 
#------------------------------------------------------------- 










7,13)), tau1 = c(1,1,NA,NA,NA,NA,1,1,NA,NA,NA,NA,1), tau2 =  












A.1.3.  ABE and PBE WinBUGS Code for FDA Drug 14c Data 
 
#BAYESIAN METHODS FOR BIOEQUIVALENCE ALENCES STUDIES 
#CODE FOR MODELS I1 USING FDA DRUG 14C DATA ON 13 PRIORS 
 
#alpha is a common intercept parameter 
#x[i,1] are the sequence indicators 
#x[i,2]-x[i,4] are the period indicators 
#x[i,5] is treatment indicator 
#s[g[i]] corresponds to the random subject (sequence) effect 
#g[i] is a variable that assigns a common subject number to each set of 





for (m in 1:13){ 
 
for (i in 1:76) { 
 z[i,m]<-log(y[i]) 






for (i in 77:N){ 
 z[i,m]<-log(y[i]) 






for (k in 1:38){ 
 s[k,m]~dnorm (alpha[m],tau3[m])  #assumption of normal 
random subject effects 
 } 
 














#Here we calculate the probability of equivalence in means, equivalence 






#The fixed effects parameters get diffuse normal prior distributions 














#  PRIOR DISTRIBUTIONS ON SCALE PARAMETERS 
#---------------------------------------------------------- 






list(alpha = c(0,0,0,0,0,0,0,0,0,0,0,0,0), 
beta=structure(.Data=c(0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,
0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
,0,0,0,0,0),.Dim=c(5,13)), tau1 = c(1,1,NA,NA,NA,NA,1,1,NA,NA,NA,NA,1), 













A.2.  WinBUGS Code for Individual Bioequivalence 
 
A.2.0.  Prior Distributions 
 
#---------------------------------------------------------------------- 
# PRIORS ON SCALE PARAMETERS:  PRIOR #1 - GAMMA(0.001,0.001) ON 
PRECISION 
#---------------------------------------------------------------------- 
TAUBR ~ dgamma(0.001, 0.001) 
TAUBT ~ dgamma(0.001, 0.001) 
tau[1] ~ dgamma( 0.001, 0.001) 








# PRIORS ON SCALE PARAMETERS:  PRIOR #2 - GAMMA(0.1,0.1) ON PRECISION 
#---------------------------------------------------------------------- 
TAUBR ~ dgamma(0.1, 0.1) 
TAUBT ~ dgamma(0.1, 0.1) 
tau[1] ~ dgamma( 0.1, 0.1) 








# PRIORS ON SCALE PARAMETERS:  PRIOR #3 - UNIFORM(-10,10) ON LOG 
VARIANCE 
#---------------------------------------------------------------------- 
lvWR ~ dunif(-10,10) 
lvWT ~ dunif(-10,10) 
lvBR ~ dunif(-10,10) 













# PRIORS ON SCALE PARAMETERS:  PRIOR 4 - UNIFORM(-10,4) ON LOG VARIANCE 
#---------------------------------------------------------------------- 
lvWR ~ dunif(-10,4) 
lvWT ~ dunif(-10,4) 
lvBR ~ dunif(-10,4) 














# PRIORS ON SCALE PARAMETERS:  PRIOR 5 - UNIFORM(0, 1000) ON VARIANCE 
#---------------------------------------------------------------------- 
S2WR ~ dunif(0,1000) 
S2WT ~ dunif(0,1000) 
S2BR ~ dunif(0,1000) 








# PRIORS ON SCALE PARAMETERS:  PRIOR 6 - UNIFORM(0, 4) ON VARIANCE 
#---------------------------------------------------------------------- 
S2WR ~ dunif(0,4) 
S2WT ~ dunif(0,4) 
S2BR ~ dunif(0,4) 








# PRIORS ON SCALE PARAMETERS:  PRIOR 7 - PARETO(1,0.001) ON PRECISION 
#---------------------------------------------------------------------- 
tau[1] ~ dpar(1,0.001) 
tau[2] ~ dpar(1,0.001) 
TAUBR ~ dpar(1,0.001) 








# PRIORS ON SCALE PARAMETERS:  PRIOR 8 - PARETO(1,0.25) ON PRECISION 
#---------------------------------------------------------------------- 
tau[1] ~ dpar(1,0.1) 
tau[2] ~ dpar(1,0.1) 
TAUBR ~ dpar(1,0.1) 





















sdWR ~ dunif(0,100) 
sdWT ~ dunif(0,100) 
sdBR ~ dunif(0,100) 
sdBT ~ dunif(0,100)  
 
#---------------------------------------------------------------------- 












sdWR ~ dunif(0,2) 
sdWT ~ dunif(0,2) 
sdBR ~ dunif(0,2) 
sdBT ~ dunif(0,2)  
 
#---------------------------------------------------------------------- 












sdWR ~ dnorm(0,0.01)I(0,) 
sdWT ~ dnorm(0,0.01)I(0,) 
sdBR ~ dnorm(0,0.01)I(0,) 
sdBT ~ dnorm(0,0.01)I(0,) 
 
#---------------------------------------------------------------------- 












sdWR ~ dnorm(0,1)I(0,) 
sdWT ~ dnorm(0,1)I(0,) 
 67 
sdBR ~ dnorm(0,1)I(0,) 
sdBT ~ dnorm(0,1)I(0,)  
 
#---------------------------------------------------------------------- 
# PRIORS ON SCALE PARAMETERS:  PRIOR 13 - ORIGINAL DIFFUSE PRIORS 
#---------------------------------------------------------------------- 
TAUBR ~ dgamma(0.0001, 0.0001) 
TAUBT ~ dgamma(0.0001, 0.0001) 
tau[1] ~ dgamma( 0.0001, 0.0001) 







A.2.1.  WinBUGS Code without carry-over effect for FDA Drug 8 Data 
 






for (i in 1:(n*REP*DRUGS)){ 
z[i]<-log(y[i]) 
z[i]~dnorm( mu[i], tau[trt[i]]) 
mu[i] <- m[ trt[i] ] + gamma[ seq[i], trt[i], rep[i] ] + delta[ 
subj[i], seq[i], trt[i] ]; 
 } 
 
for (j in 1:n){ 
 for (i in 1:SEQ){ 
  delta[j,i,1:DRUGS]~dmnorm( meand[] , T[,] ); 








# VARIANCES:  
#---------------------------------------------------------------------- 
# S2BR : Between-subject variance for Test drug formulation treatment 
# S2BT : Between-subject variance for Reference drug formulation 
Treatment 
# S2WR : within-subject variance for reference drug formulation 
treatment 
# S2WT : within-subject variance for test drug formulation treatment 
# S2D : variance treatment difference 
# S2TT : total variance from Test drug formulation population 
















# SECOND STAGE OF HYPERPRIORS 
for (k in 1:DRUGS) { 
# constraint 
 gamma[1,k,1]<- -gamma[1,k,2] -gamma[2,k,1]-gamma[2,k,2] 
 
 for (i in 2:SEQ){ gamma[i,k,1] ~ dnorm( g[k], taug[k]) } 
 for (l in 2:REP){ gamma[1,k,l] ~ dnorm( g[k], taug[k]) } 
 for (i in 2:SEQ){ for (l in 2:REP){ gamma[i,k,l] ~ dnorm( g[k], 
taug[k] ) }} 
 g[k]<-0.0 
 taug[k]<-0.0001 
 m[k] ~ dnorm( m00, tau0[k]) 
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tau0[k] ~ dgamma(0.0001, 0.0001)  
 } 
 
m00 ~ dnorm(0.0, 0.0001) 
 
#------------------------------------------------------- 
# BIOEQUIVALENCE PARAMETERS 
#------------------------------------------------------- 
 
# INDIVIDUAL BIOEQUIVALENCE 
 
S2W0 <- 0.04 
THETAI <- 2.4948 
IBE <- ( (m[2]-m[1])*(m[2]-m[1]) + S2D + S2WT - S2WR) / max(S2WR, S2W0) 
IBEH0 <- step( IBE-THETAI ) 
 
#---------------------------------------------------------------------- 
# PRIORS ON SCALE PARAMETERS:   
#---------------------------------------------------------------------- 






list(m00 = 0, rho = 0, tau0 = c(1,1),***Initial Values for Scale 
Parameters Go Here***) 
 
***NOTE:  The initial values for the scale parameters will depend on which scale 
parameter is being modeled stochastically.  The initial values for the scale parameters 
used were: 
 
For Priors 1, 2, 7, 8, and 13: 
tau = c(1,1) 
TAUBR = 1  
TAUBT = 1 
 
For Priors 3 and 4: 
lvWR = 1 
lvWT = 1  
lvBR = 1 
lvBT = 1  
 
For Priors 5 and 6: 
S2WR = 1  
S2WT = 1  
S2BR = 1  
S2BT = 1  
 
For Priors 9, 10, 11, and 12: 
sdWR = 1 
sdWT = 1  
sdBR = 1 
sdBT = 1  
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A.2.2.  WinBUGS Code without carry-over effect for FDA Drug 14c Data 
 






for (i in 1:(n*REP*DRUGS)){ 
 z[i]<-log(y[i]) 
 z[i]~dnorm( mu[i], tau[trt[i]]) 
 mu[i] <- m[ trt[i] ] + gamma[ seq[i], trt[i], rep[i] ] + delta[ 
subj[i], seq[i], trt[i] ]; 
 } 
 
for (j in 1:n){ 
 for (i in 1:SEQ){ 
  delta[j,i,1:DRUGS]~dmnorm( meand[] , T[,] ); 








# VARIANCES:  
#---------------------------------------------------------------------- 
# S2BR : Between-subject variance for Test drug formulation treatment 
# S2BT : Between-subject variance for Reference drug formulation 
Treatment 
# S2WR : within-subject variance for reference drug formulation 
treatment 
# S2WT : within-subject variance for test drug formulation treatment 
# S2D : variance treatment difference 
# S2TT : total variance from Test drug formulation population 
















# SECOND STAGE OF HYPERPRIORS 
for (k in 1:DRUGS) { 
# constraint 
 gamma[1,k,1]<- -gamma[1,k,2] -gamma[2,k,1]-gamma[2,k,2] 
 
 for (i in 2:SEQ){ gamma[i,k,1] ~ dnorm( g[k], taug[k]) } 
 for (l in 2:REP){ gamma[1,k,l] ~ dnorm( g[k], taug[k]) } 
 for (i in 2:SEQ){ for (l in 2:REP){ gamma[i,k,l] ~ dnorm( g[k], 
taug[k] ) }} 
 g[k]<-0.0 
 taug[k]<-0.0001 
 m[k] ~ dnorm( m00, tau0[k]) 
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m00 ~ dnorm(0.0, 0.0001) 
 
#------------------------------------------------------- 
# BIOEQUIVALENCE PARAMETERS 
#------------------------------------------------------- 
 
# INDIVIDUAL BIOEQUIVALENCE 
 
S2W0 <- 0.04 
THETAI <- 2.4948 
IBE <- ( (m[2]-m[1])*(m[2]-m[1]) + S2D + S2WT - S2WR) / max(S2WR, S2W0) 
IBEH0 <- step( IBE-THETAI ) 
 
#---------------------------------------------------------------------- 
# PRIORS ON SCALE PARAMETERS: 
#---------------------------------------------------------------------- 






list(m00 = 0, rho = 0, tau0 = c(1,1),***Initial Values for Scale 
Parameters Go Here***) 
 
***NOTE:  The initial values for the scale parameters will depend on which scale 
parameter is being modeled stochastically.  The initial values for the scale parameters 
used were: 
 
For Priors 1, 2, 7, 8, and 13: 
tau = c(1,1) 
TAUBR = 1  
TAUBT = 1 
 
For Priors 3 and 4: 
lvWR = 1 
lvWT = 1  
lvBR = 1 
lvBT = 1  
 
For Priors 5 and 6: 
S2WR = 1  
S2WT = 1  
S2BR = 1  
S2BT = 1  
 
For Priors 9, 10, 11, and 12: 
sdWR = 1 
sdWT = 1  
sdBR = 1 
sdBT = 1  
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A.2.3.  WinBUGS Code with carry-over effect for FDA Drug 14c Data 
 






for (i in 1:(n*REP*DRUGS)){ 
 z[i]<-log(y[i]) 
 z[i]~dnorm( mu[i], tau[trt[i]]) 
 mu[i] <- m[ trt[i] ]+gamma[ seq[i], trt[i], rep[i] ]+delta[ 
subj[i], seq[i], trt[i] ]+r[i]*lambda;    
 } 
 
# Prior Distribution for carry-over effect lambda 
lambda~dnorm(0,0.0001) 
 
for (j in 1:n){ 
 for (i in 1:SEQ){ 
  delta[j,i,1:DRUGS]~dmnorm( meand[] , T[,] ); 








# VARIANCES:  
#---------------------------------------------------------------------- 
# S2BR : Between-subject variance for Test drug formulation treatment 
# S2BT : Between-subject variance for Reference drug formulation 
Treatment 
# S2WR : within-subject variance for reference drug formulation 
treatment 
# S2WT : within-subject variance for test drug formulation treatment 
# S2D : variance treatment difference 
# S2TT : total variance from Test drug formulation population 
















# Prior Distribution for gamma 
#--------------------------------------------------------------- 
# SECOND STAGE OF HYPERPRIORS 
for (k in 1:DRUGS) { 
# constraint 
 gamma[1,k,1]<- -gamma[1,k,2] -gamma[2,k,1]-gamma[2,k,2] 
 
 for (i in 2:SEQ){ gamma[i,k,1] ~ dnorm( g[k], taug[k]) } 
 for (l in 2:REP){ gamma[1,k,l] ~ dnorm( g[k], taug[k]) } 
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 for (i in 2:SEQ){ for (l in 2:REP){ gamma[i,k,l] ~ dnorm( g[k], 
taug[k] ) }} 
 g[k]<-0.0 
 taug[k]<-0.0001 
 m[k] ~ dnorm( m00, tau0[k]) 
 tau0[k] ~ dgamma(0.0001, 0.0001)  
 } 
m00 ~ dnorm(0.0, 0.0001) 
 
#------------------------------------------------------- 
# BIOEQUIVALENCE PARAMETERS 
#------------------------------------------------------- 
 
# INDIVIDUAL BIOEQUIVALENCE 
 
S2W0 <- 0.04 
THETAI <- 2.4948 
IBE <- ( (m[2]-m[1])*(m[2]-m[1]) + S2D + S2WT - S2WR) / max(S2WR, S2W0) 
IBEH0 <- step( IBE-THETAI ) 
 
#---------------------------------------------------------------------- 
# PRIORS ON SCALE PARAMETERS:  ORIGINAL DIFFUSE PRIORS 
#---------------------------------------------------------------------- 






list(m00 = 0, rho = 0, lambda = 0, tau0 = c(1,1),***Initial Values for 
Scale Parameters Go Here***) 
 
***NOTE:  The initial values for the scale parameters will depend on which scale 
parameter is being modeled stochastically.  The initial values for the scale parameters 
used were: 
 
For Priors 1, 2, 7, 8, and 13: 
tau = c(1,1) 
TAUBR = 1  
TAUBT = 1 
 
For Priors 3 and 4: 
lvWR = 1 
lvWT = 1  
lvBR = 1 
lvBT = 1  
 
For Priors 5 and 6: 
S2WR = 1  
S2WT = 1  
S2BR = 1  
S2BT = 1  
 
For Priors 9, 10, 11, and 12: 
sdWR = 1 
sdWT = 1  
sdBR = 1 




A.3.1.  Chow and Liu Data for ABE and PBE 
 
#Chow & Liu data 
#input y[]=AUCt seq indicators(X1), per indicators(X2), trt 
indicator(X3), subj(g) 
 
#  CODING OF VARIABLES 
#--------------------------------------------------------- 
# seq x[,1] 
# 1 0 
# 2 1 
#--------------------------------------------------------- 
# per x[,2] 
# 1 0 
# 2 1 
#--------------------------------------------------------- 
# trt x[,3] 
# 1 0 




y[]  x[,1] x[,2] x[,3] g[] 
74.675 0 0 0 1 
96.4  0 0 0 4 
101.95 0 0 0 5 
79.05  0 0 0 6 
79.05  0 0 0 11 
85.95  0 0 0 12 
69.725 0 0 0 15 
86.275 0 0 0 16 
112.675 0 0 0 19 
99.525 0 0 0 20 
89.425 0 0 0 23 
55.175 0 0 0 24 
37.35  1 1 0 2 
51.925 1 1 0 3 
72.175 1 1 0 7 
77.5  1 1 0 8 
71.875 1 1 0 9 
94.025 1 1 0 10 
124.975 1 1 0 13 
85.225 1 1 0 14 
95.925 1 1 0 17 
67.1  1 1 0 18 
59.425 1 1 0 21 
114.05 1 1 0 22 
73.675 0 1 1 1 
93.25  0 1 1 4 
102.125 0 1 1 5 
69.45  0 1 1 6 
69.025 0 1 1 11 
68.7  0 1 1 12 
59.425 0 1 1 15 
76.125 0 1 1 16 
114.875 0 1 1 19 
116.25 0 1 1 20 
64.175 0 1 1 23 
74.575 0 1 1 24 
74.825 1 0 1 2 
86.875 1 0 1 3 
81.675 1 0 1 7 
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92.7  1 0 1 8 
50.45  1 0 1 9 
66.125 1 0 1 10 
122.45 1 0 1 13 
99.075 1 0 1 14 
86.35  1 0 1 17 
49.925 1 0 1 18 
42.7  1 0 1 21 








#Input y[]=AUCt, seq=(x[,1]-x[,3]), per=(x[,4]-x[,6]), trt=x[,7], 
g[]=subj 
 
#  CODING OF VARIABLES 
#--------------------------------------------------------- 






# seq x[,1] x[,2] x[,3]  
# 1 0 0 0  
# 2 0 0 1  
# 3 0 1 0  
# 4 1 0 0  
#--------------------------------------------------------- 
# Period Coding 
# per x[,4] x[,5] x[,6] 
# 1 0 0 0 
# 2 0 0 1 
# 3 0 1 0 
# 4 1 0 0 
#--------------------------------------------------------- 
# Treatment Coding 
# Trt 1= Test 
# Trt 2= Reference 
# 
# trt x[,7] 
# 1 0 




y[]  x[,1] x[,2] x[,3] x[,4] x[,5] x[,6] x[,7] g[] 
1927.4 0 0 0 0 0 0 1 1 
1526.5 0 0 0 0 0 1 1 1 
3219.1 0 0 1 0 0 1 1 2 
2933  0 0 1 0 1 0 1 2 
2816.6 0 1 0 0 1 0 1 3 
3078.3 0 1 0 1 0 0 1 3 
1477.2 1 0 0 0 0 0 1 4 
1948.3 1 0 0 1 0 0 1 4 
2177.7 0 0 0 0 0 0 1 5 
1780.6 0 0 0 0 0 1 1 5 
2354.3 1 0 0 0 0 0 1 6 
3275  1 0 0 1 0 0 1 6 
667.4  0 0 1 0 0 1 1 7 
1274.4 0 0 1 0 1 0 1 7 
2332.5 0 1 0 0 1 0 1 8 
2310.9 0 1 0 1 0 0 1 8 
2137  0 1 0 0 1 0 1 9 
2035.1 0 1 0 1 0 0 1 9 
2106.1 1 0 0 0 0 0 1 10 
2335.8 1 0 0 1 0 0 1 10 
1344.8 0 0 1 0 0 1 1 11 
1608.3 0 0 1 0 1 0 1 11 
2962.7 0 0 0 0 0 0 1 12 
1403.7 0 0 0 0 0 1 1 12 
1968.9 0 0 0 0 0 0 1 13 
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1971.6 0 0 0 0 0 1 1 13 
1661.4 0 0 1 0 0 1 1 14 
2226.2 0 0 1 0 1 0 1 14 
1664.4 1 0 0 0 0 0 1 15 
1881.6 1 0 0 1 0 0 1 15 
2082.5 0 0 1 0 0 1 1 16 
2085.5 0 0 1 0 1 0 1 16 
2125.1 0 1 0 0 1 0 1 17 
1245.9 0 1 0 1 0 0 1 17 
2211.8 1 0 0 0 0 0 1 18 
3123.3 1 0 0 1 0 0 1 18 
2074.6 0 0 1 0 0 1 1 19 
1828.6 0 0 1 0 1 0 1 19 
1880.4 0 0 0 0 1 0 0 1 
1522.5 0 0 0 1 0 0 0 1 
1065.3 0 0 1 0 0 0 0 2 
2131.3 0 0 1 1 0 0 0 2 
5091.9 0 1 0 0 0 0 0 3 
4193.4 0 1 0 0 0 1 0 3 
2985.1 1 0 0 0 0 1 0 4 
2157.7 1 0 0 0 1 0 0 4 
2509.7 0 0 0 0 1 0 0 5 
2885.3 0 0 0 1 0 0 0 5 
2416.6 1 0 0 0 0 1 0 6 
3092.6 1 0 0 0 1 0 0 6 
1212  0 0 1 0 0 0 0 7 
963.6  0 0 1 1 0 0 0 7 
1850.6 0 1 0 0 0 0 0 8 
2785  0 1 0 0 0 1 0 8 
1607.3 0 1 0 0 0 0 0 9 
1538.8 0 1 0 0 0 1 0 9 
2374.4 1 0 0 0 0 1 0 10 
1674.1 1 0 0 0 1 0 0 10 
1110.8 0 0 1 0 0 0 0 11 
1536.2 0 0 1 1 0 0 0 11 
2238.7 0 0 0 0 1 0 0 12 
2354.9 0 0 0 1 0 0 0 12 
1374.3 0 0 0 0 1 0 0 13 
1608  0 0 0 1 0 0 0 13 
2524.7 0 0 1 0 0 0 0 14 
1526.1 0 0 1 1 0 0 0 14 
2096.4 1 0 0 0 0 1 0 15 
2147.7 1 0 0 0 1 0 0 15 
1537.1 0 0 1 0 0 0 0 16 
1768.8 0 0 1 1 0 0 0 16 
2050.4 0 1 0 0 0 0 0 17 
2082.3 0 1 0 0 0 1 0 17 
3631.3 1 0 0 0 0 1 0 18 
2880.2 1 0 0 0 1 0 0 18 
1743.2 0 0 1 0 0 0 0 19 




A.4.2.  FDA Drug 8 Data for IBE 
 
#       Drug 8 
# Trt 1= Test 




subj[] seq[] rep[] trt[] y[] 
1 1 1 2 1927.4 
1 1 2 2 1526.5 
1 1 1 1 1880.4 
1 1 2 1 1522.5 
2 2 1 1 1065.3 
2 2 1 2 3219.1 
2 2 2 2 2933 
2 2 2 1 2131.3 
3 3 1 1 5091.9 
3 3 2 1 4193.4 
3 3 1 2 2816.6 
3 3 2 2 3078.3 
4 4 1 2 1477.2 
4 4 1 1 2985.1 
4 4 2 1 2157.7 
4 4 2 2 1948.3 
5 1 1 2 2177.7 
5 1 2 2 1780.6 
5 1 1 1 2509.7 
5 1 2 1 2885.3 
6 4 1 2 2354.3 
6 4 1 1 2416.6 
6 4 2 1 3092.6 
6 4 2 2 3275 
7 2 1 1 1212 
7 2 1 2 667.4 
7 2 2 2 1274.4 
7 2 2 1 963.6 
8 3 1 1 1850.6 
8 3 2 1 2785 
8 3 1 2 2332.5 
8 3 2 2 2310.9 
9 3 1 1 1607.3 
9 3 2 1 1538.8 
9 3 1 2 2137 
9 3 2 2 2035.1 
10 4 1 2 2106.1 
10 4 1 1 2374.4 
10 4 2 1 1674.1 
10 4 2 2 2335.8 
11 2 1 1 1110.8 
11 2 1 2 1344.8 
11 2 2 2 1608.3 
11 2 2 1 1536.2 
12 1 1 2 2962.7 
12 1 2 2 1403.7 
12 1 1 1 2238.7 
12 1 2 1 2354.9 
13 1 1 2 1968.9 
13 1 2 2 1971.6 
13 1 1 1 1374.3 
13 1 2 1 1608 
14 2 1 1 2524.7 
14 2 1 2 1661.4 
14 2 2 2 2226.2 
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14 2 2 1 1526.1 
15 4 1 2 1664.4 
15 4 1 1 2096.4 
15 4 2 1 2147.7 
15 4 2 2 1881.6 
16 2 1 1 1537.1 
16 2 1 2 2082.5 
16 2 2 2 2085.5 
16 2 2 1 1768.8 
17 3 1 1 2050.4 
17 3 2 1 2082.3 
17 3 1 2 2125.1 
17 3 2 2 1245.9 
18 4 1 2 2211.8 
18 4 1 1 3631.3 
18 4 2 1 2880.2 
18 4 2 2 3123.3 
19 2 1 1 1743.2 
19 2 1 2 2074.6 
19 2 2 2 1828.6 




A.5.1.  FDA Drug 14c Data for ABE and PBE 
 
# DRUG 14C FROM FDA WEBSITE 
# input y[]=AUCt g[]=SUBJ 
#  CODING OF VARIABLES 
#--------------------------------------------------------- 
# seq x[,1] 
# 1 0 
# 2 1 
#--------------------------------------------------------- 
# per x[,2] X[,3] X[,4] 
# 1 0 0 0 
# 2 1 0 0 
# 3 0 1 0 
# 4 0 0 1  
#--------------------------------------------------------- 
# trt x[,5] 
# 1 0 




y[] x[,1] x[,2] x[,3] x[,4] x[,5] g[] 
346.657 1 0 0 0 1 1 
333.783 1 0 0 1 1 1 
271.828 1 0 0 0 1 2 
330.27 1 0 0 1 1 2 
295.662 0 1 0 0 1 3 
272.292 0 0 1 0 1 3 
347.456 1 0 0 0 1 4 
377.844 1 0 0 1 1 4 
329.069 1 0 0 0 1 5 
270.104 1 0 0 1 1 5 
385.956 0 1 0 0 1 6 
376.274 0 0 1 0 1 6 
311.421 1 0 0 0 1 7 
331.277 1 0 0 1 1 7 
266.97 0 1 0 0 1 8 
209.216 0 0 1 0 1 8 
193.216 0 1 0 0 1 9 
210.969 0 0 1 0 1 9 
313.162 0 1 0 0 1 10 
293.487 0 0 1 0 1 10 
287.225 0 1 0 0 1 11 
327.839 0 0 1 0 1 11 
312.111 0 1 0 0 1 12 
330.896 0 0 1 0 1 12 
272.382 0 1 0 0 1 13 
252.822 0 0 1 0 1 13 
319.934 1 0 0 0 1 14 
342.512 1 0 0 1 1 14 
197.386 0 1 0 0 1 15 
224.63 0 0 1 0 1 15 
317.494 0 1 0 0 1 16 
314.604 0 0 1 0 1 16 
353.662 0 1 0 0 1 17 
345.82 0 0 1 0 1 17 
189.886 1 0 0 0 1 18 
245.583 1 0 0 1 1 18 
214.754 0 1 0 0 1 19 
142.514 0 0 1 0 1 19 
263.031 1 0 0 0 1 20 
271.879 1 0 0 1 1 20 
273.088 1 0 0 0 1 21 
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253.794 1 0 0 1 1 21 
307.58 0 1 0 0 1 22 
364.567 0 0 1 0 1 22 
279.311 1 0 0 0 1 23 
298.579 1 0 0 1 1 23 
398.39 0 1 0 0 1 24 
352.844 0 0 1 0 1 24 
314.791 1 0 0 0 1 25 
326.895 1 0 0 1 1 25 
381.913 1 0 0 0 1 26 
268.906 1 0 0 1 1 26 
217.423 0 1 0 0 1 27 
186.125 0 0 1 0 1 27 
176.912 1 0 0 0 1 28 
169.195 1 0 0 1 1 28 
274.946 1 0 0 0 1 29 
245.503 1 0 0 1 1 29 
386.77 0 1 0 0 1 30 
325.938 0 0 1 0 1 30 
207.374 1 0 0 0 1 31 
304.305 1 0 0 1 1 31 
313.213 0 1 0 0 1 32 
253.484 0 0 1 0 1 32 
179.864 1 0 0 0 1 33 
186.623 1 0 0 1 1 33 
188.034 1 0 0 0 1 34 
198.137 1 0 0 1 1 34 
320.177 0 1 0 0 1 35 
243.794 0 0 1 0 1 35 
139.147 1 0 0 0 1 36 
188.801 1 0 0 1 1 36 
321.509 1 0 0 0 1 37 
325.621 1 0 0 1 1 37 
341.441 1 0 0 0 1 38 
329.299 1 0 0 1 1 38 
295.793 1 1 0 0 0 1 
307.487 1 0 1 0 0 1 
268.853 1 1 0 0 0 2 
297.293 1 0 1 0 0 2 
288.982 0 0 0 0 0 3 
288.023 0 0 0 1 0 3 
315.592 1 1 0 0 0 4 
368.771 1 0 1 0 0 4 
267.528 1 1 0 0 0 5 
259.507 1 0 1 0 0 5 
313.583 0 0 0 0 0 6 
409.134 0 0 0 1 0 6 
260.449 1 1 0 0 0 7 
255.399 1 0 1 0 0 7 
251  0 0 0 0 0 8 
276.414 0 0 0 1 0 8 
200.429 0 0 0 0 0 9 
234.662 0 0 0 1 0 9 
300.113 0 0 0 0 0 10 
349.199 0 0 0 1 0 10 
259.098 0 0 0 0 0 11 
274.848 0 0 0 1 0 11 
292.694 0 0 0 0 0 12 
271.354 0 0 0 1 0 12 
382.436 0 0 0 0 0 13 
290.16 0 0 0 1 0 13 
286.001 1 1 0 0 0 14 
284.307 1 0 1 0 0 14 
165.711 0 0 0 0 0 15 
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216.986 0 0 0 1 0 15 
321.386 0 0 0 0 0 16 
343.271 0 0 0 1 0 16 
324.899 0 0 0 0 0 17 
311.822 0 0 0 1 0 17 
202.821 1 1 0 0 0 18 
379.1  1 0 1 0 0 18 
182.509 0 0 0 0 0 19 
237.114 0 0 0 1 0 19 
285.758 1 1 0 0 0 20 
309.356 1 0 1 0 0 20 
201.809 1 1 0 0 0 21 
232.005 1 0 1 0 0 21 
254.868 0 0 0 0 0 22 
233.719 0 0 0 1 0 22 
320.763 1 1 0 0 0 23 
253.281 1 0 1 0 0 23 
343.725 0 0 0 0 0 24 
290.404 0 0 0 1 0 24 
340.947 1 1 0 0 0 25 
306.799 1 0 1 0 0 25 
314.845 1 1 0 0 0 26 
288.623 1 0 1 0 0 26 
192.33 0 0 0 0 0 27 
174.125 0 0 0 1 0 27 
170.607 1 1 0 0 0 28 
179.668 1 0 1 0 0 28 
285.287 1 1 0 0 0 29 
205.17 1 0 1 0 0 29 
382.929 0 0 0 0 0 30 
337.494 0 0 0 1 0 30 
242.771 1 1 0 0 0 31 
257.696 1 0 1 0 0 31 
225.137 0 0 0 0 0 32 
447.483 0 0 0 1 0 32 
202.77 1 1 0 0 0 33 
202.892 1 0 1 0 0 33 
236.78 1 1 0 0 0 34 
263.08 1 0 1 0 0 34 
239.068 0 0 0 0 0 35 
299.003 0 0 0 1 0 35 
144.593 1 1 0 0 0 36 
188.394 1 0 1 0 0 36 
323.345 1 1 0 0 0 37 
312.701 1 0 1 0 0 37 
355.642 1 1 0 0 0 38 




A.5.2.  FDA Drug 14c Data for IBE without carry-over 
 
#        Drug 14c. 
#        Replicate Design 
#        Trt 1: Test 




seq[] subj[] trt[] rep[] y[] 
2 1 1 1 295.793 
2 1 2 1 346.657 
2 1 1 2 307.487 
2 1 2 2 333.783 
2 2 1 1 268.853 
2 2 2 1 271.828 
2 2 1 2 297.293 
2 2 2 2 330.27 
1 3 1 1 288.982 
1 3 2 1 295.662 
1 3 1 2 288.023 
1 3 2 2 272.292 
2 4 1 1 315.592 
2 4 2 1 347.456 
2 4 1 2 368.771 
2 4 2 2 377.844 
2 5 1 1 267.528 
2 5 2 1 329.069 
2 5 1 2 259.507 
2 5 2 2 270.104 
1 6 1 1 313.583 
1 6 2 1 385.956 
1 6 1 2 409.134 
1 6 2 2 376.274 
2 7 1 1 260.449 
2 7 2 1 311.421 
2 7 1 2 255.399 
2 7 2 2 331.277 
1 8 1 1 251 
1 8 2 1 266.97 
1 8 1 2 276.414 
1 8 2 2 209.216 
1 9 1 1 200.429 
1 9 2 1 193.216 
1 9 1 2 234.662 
1 9 2 2 210.969 
1 10 1 1 300.113 
1 10 2 1 313.162 
1 10 1 2 349.199 
1 10 2 2 293.487 
1 11 1 1 259.098 
1 11 2 1 287.225 
1 11 1 2 274.848 
1 11 2 2 327.839 
1 12 1 1 292.694 
1 12 2 1 312.111 
1 12 1 2 271.354 
1 12 2 2 330.896 
1 13 1 1 382.436 
1 13 2 1 272.382 
1 13 1 2 290.16 
1 13 2 2 252.822 
2 14 1 1 286.001 
2 14 2 1 319.934 
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2 14 1 2 284.307 
2 14 2 2 342.512 
1 15 1 1 165.711 
1 15 2 1 197.386 
1 15 1 2 216.986 
1 15 2 2 224.63 
1 16 1 1 321.386 
1 16 2 1 317.494 
1 16 1 2 343.271 
1 16 2 2 314.604 
1 17 1 1 324.899 
1 17 2 1 353.662 
1 17 1 2 311.822 
1 17 2 2 345.82 
2 18 1 1 202.821 
2 18 2 1 189.886 
2 18 1 2 379.1 
2 18 2 2 245.583 
1 19 1 1 182.509 
1 19 2 1 214.754 
1 19 1 2 237.114 
1 19 2 2 142.514 
2 20 1 1 285.758 
2 20 2 1 263.031 
2 20 1 2 309.356 
2 20 2 2 271.879 
2 21 1 1 201.809 
2 21 2 1 273.088 
2 21 1 2 232.005 
2 21 2 2 253.794 
1 22 1 1 254.868 
1 22 2 1 307.58 
1 22 1 2 233.719 
1 22 2 2 364.567 
2 23 1 1 320.763 
2 23 2 1 279.311 
2 23 1 2 253.281 
2 23 2 2 298.579 
1 24 1 1 343.725 
1 24 2 1 398.39 
1 24 1 2 290.404 
1 24 2 2 352.844 
2 25 1 1 340.947 
2 25 2 1 314.791 
2 25 1 2 306.799 
2 25 2 2 326.895 
2 26 1 1 314.845 
2 26 2 1 381.913 
2 26 1 2 288.623 
2 26 2 2 268.906 
1 27 1 1 192.33 
1 27 2 1 217.423 
1 27 1 2 174.125 
1 27 2 2 186.125 
2 28 1 1 170.607 
2 28 2 1 176.912 
2 28 1 2 179.668 
2 28 2 2 169.195 
2 29 1 1 285.287 
2 29 2 1 274.946 
2 29 1 2 205.17 
2 29 2 2 245.503 
1 30 1 1 382.929 
1 30 2 1 386.77 
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1 30 1 2 337.494 
1 30 2 2 325.938 
2 31 1 1 242.771 
2 31 2 1 207.374 
2 31 1 2 257.696 
2 31 2 2 304.305 
1 32 1 1 225.137 
1 32 2 1 313.213 
1 32 1 2 447.483 
1 32 2 2 253.484 
2 33 1 1 202.77 
2 33 2 1 179.864 
2 33 1 2 202.892 
2 33 2 2 186.623 
2 34 1 1 236.78 
2 34 2 1 188.034 
2 34 1 2 263.08 
2 34 2 2 198.137 
1 35 1 1 239.068 
1 35 2 1 320.177 
1 35 1 2 299.003 
1 35 2 2 243.794 
2 36 1 1 144.593 
2 36 2 1 139.147 
2 36 1 2 188.394 
2 36 2 2 188.801 
2 37 1 1 323.345 
2 37 2 1 321.509 
2 37 1 2 312.701 
2 37 2 2 325.621 
2 38 1 1 355.642 
2 38 2 1 341.441 
2 38 1 2 400.55 
2 38 2 2 329.299 
END 
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A.5.3.  FDA Drug 14c Data for IBE with carry-over 
 
#        Drug 14c. 
#        Replicate Design 
#        Trt 1: Test 
#        Trt 2: Reference 
 
# CODING OR INDICATOR VARIABLE r 
#---------------------------------------- 





seq[] subj[] trt[] rep[] r[] y[] 
2 1 1 1 1 295.793 
2 1 2 1 0 346.657 
2 1 1 2 1 307.487 
2 1 2 2 1 333.783 
2 2 1 1 1 268.853 
2 2 2 1 0 271.828 
2 2 1 2 1 297.293 
2 2 2 2 1 330.27 
1 3 1 1 0 288.982 
1 3 2 1 1 295.662 
1 3 1 2 1 288.023 
1 3 2 2 1 272.292 
2 4 1 1 1 315.592 
2 4 2 1 0 347.456 
2 4 1 2 1 368.771 
2 4 2 2 1 377.844 
2 5 1 1 1 267.528 
2 5 2 1 0 329.069 
2 5 1 2 1 259.507 
2 5 2 2 1 270.104 
1 6 1 1 0 313.583 
1 6 2 1 1 385.956 
1 6 1 2 1 409.134 
1 6 2 2 1 376.274 
2 7 1 1 1 260.449 
2 7 2 1 0 311.421 
2 7 1 2 1 255.399 
2 7 2 2 1 331.277 
1 8 1 1 0 251 
1 8 2 1 1 266.97 
1 8 1 2 1 276.414 
1 8 2 2 1 209.216 
1 9 1 1 0 200.429 
1 9 2 1 1 193.216 
1 9 1 2 1 234.662 
1 9 2 2 1 210.969 
1 10 1 1 0 300.113 
1 10 2 1 1 313.162 
1 10 1 2 1 349.199 
1 10 2 2 1 293.487 
1 11 1 1 0 259.098 
1 11 2 1 1 287.225 
1 11 1 2 1 274.848 
1 11 2 2 1 327.839 
1 12 1 1 0 292.694 
1 12 2 1 1 312.111 
1 12 1 2 1 271.354 
1 12 2 2 1 330.896 
1 13 1 1 0 382.436 
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1 13 2 1 1 272.382 
1 13 1 2 1 290.16 
1 13 2 2 1 252.822 
2 14 1 1 1 286.001 
2 14 2 1 0 319.934 
2 14 1 2 1 284.307 
2 14 2 2 1 342.512 
1 15 1 1 0 165.711 
1 15 2 1 1 197.386 
1 15 1 2 1 216.986 
1 15 2 2 1 224.63 
1 16 1 1 0 321.386 
1 16 2 1 1 317.494 
1 16 1 2 1 343.271 
1 16 2 2 1 314.604 
1 17 1 1 0 324.899 
1 17 2 1 1 353.662 
1 17 1 2 1 311.822 
1 17 2 2 1 345.82 
2 18 1 1 1 202.821 
2 18 2 1 0 189.886 
2 18 1 2 1 379.1 
2 18 2 2 1 245.583 
1 19 1 1 0 182.509 
1 19 2 1 1 214.754 
1 19 1 2 1 237.114 
1 19 2 2 1 142.514 
2 20 1 1 1 285.758 
2 20 2 1 0 263.031 
2 20 1 2 1 309.356 
2 20 2 2 1 271.879 
2 21 1 1 1 201.809 
2 21 2 1 0 273.088 
2 21 1 2 1 232.005 
2 21 2 2 1 253.794 
1 22 1 1 0 254.868 
1 22 2 1 1 307.58 
1 22 1 2 1 233.719 
1 22 2 2 1 364.567 
2 23 1 1 1 320.763 
2 23 2 1 0 279.311 
2 23 1 2 1 253.281 
2 23 2 2 1 298.579 
1 24 1 1 0 343.725 
1 24 2 1 1 398.39 
1 24 1 2 1 290.404 
1 24 2 2 1 352.844 
2 25 1 1 1 340.947 
2 25 2 1 0 314.791 
2 25 1 2 1 306.799 
2 25 2 2 1 326.895 
2 26 1 1 1 314.845 
2 26 2 1 0 381.913 
2 26 1 2 1 288.623 
2 26 2 2 1 268.906 
1 27 1 1 0 192.33 
1 27 2 1 1 217.423 
1 27 1 2 1 174.125 
1 27 2 2 1 186.125 
2 28 1 1 1 170.607 
2 28 2 1 0 176.912 
2 28 1 2 1 179.668 
2 28 2 2 1 169.195 
2 29 1 1 1 285.287 
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2 29 2 1 0 274.946 
2 29 1 2 1 205.17 
2 29 2 2 1 245.503 
1 30 1 1 0 382.929 
1 30 2 1 1 386.77 
1 30 1 2 1 337.494 
1 30 2 2 1 325.938 
2 31 1 1 1 242.771 
2 31 2 1 0 207.374 
2 31 1 2 1 257.696 
2 31 2 2 1 304.305 
1 32 1 1 0 225.137 
1 32 2 1 1 313.213 
1 32 1 2 1 447.483 
1 32 2 2 1 253.484 
2 33 1 1 1 202.77 
2 33 2 1 0 179.864 
2 33 1 2 1 202.892 
2 33 2 2 1 186.623 
2 34 1 1 1 236.78 
2 34 2 1 0 188.034 
2 34 1 2 1 263.08 
2 34 2 2 1 198.137 
1 35 1 1 0 239.068 
1 35 2 1 1 320.177 
1 35 1 2 1 299.003 
1 35 2 2 1 243.794 
2 36 1 1 1 144.593 
2 36 2 1 0 139.147 
2 36 1 2 1 188.394 
2 36 2 2 1 188.801 
2 37 1 1 1 323.345 
2 37 2 1 0 321.509 
2 37 1 2 1 312.701 
2 37 2 2 1 325.621 
2 38 1 1 1 355.642 
2 38 2 1 0 341.441 
2 38 1 2 1 400.55 
2 38 2 2 1 329.299 
END 
 
 
 
